AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
116_CD
Form_NN
20-F_JJ
Information_NOMZ
2005_CD
NOTES_NN
TO_PIN
THE_DT
FINANCIAL_NN
STATEMENTS_NOMZ
CONTINUED_VBD
25_CD
COMMITMENTS_NOMZ
AND_CC
CONTINGENT_JJ
LIABILITIES_NOMZ
2005 2004 2003_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Commitments_NOMZ
Contracts_NN
placed_VBD
for_PIN
future_JJ
capital_NN
expenditure_NN
not_XX0
provided_VBN
for_PIN
in_PIN
these_DEMO
accounts_NN
220 298 421_CD
Included_VBN
in_PIN
the_DT
above_PLACE
total_NN
are_VPRT [PASS]
contracts_NN
related_VBN [WZPAST]
to_PIN
certain_JJ
product_NN
purchase_NN
and_PHC
licence_NN
agreements_NOMZ
with_PIN
deferred_JJ
consideration_NOMZ
obligations_NOMZ
,_,
the_DT
amounts_NN
of_PIN
which_WDT [PIRE]
are_VPRT [BEMA]
variable_PRED
depending_VBG
upon_PIN
particular_JJ
milestone_NN
achievements_NOMZ
._.
Sales_NN
of_PIN
the_DT
products_NN
to_PIN
which_WDT [PIRE]
these_DEMO
milestones_NN
relate_VPRT
could_POMD
give_VB
rise_VB
to_PIN
additional_JJ
payments_NOMZ
,_,
contingent_NN
upon_PIN
the_DT
sales_NN
levels_NN
achieved_VBN
._.
Guarantees_NN
and_PHC
contingencies_NN
arising_VBG [WZPRES]
in_PIN
the_DT
ordinary_JJ
course_NN
of_PIN
business_NOMZ
,_,
for_PIN
which_WDT [PIRE]
no_SYNE
security_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
given_VBN
,_,
are_VPRT [PASS]
not_XX0
expected_VBN [PRIV]
to_TO
result_VB
in_PIN
any_QUAN
material_NN
financial_JJ
loss_NN
._.
During_PIN
December_NN
2005_CD
AstraZeneca_NN
entered_VBD
into_PIN
three_CD
collaboration_NOMZ
agreements_NOMZ
with_PIN
Protherics_NN
PLC_NN
,_,
Targacept_NN
,_,
Inc._NN
and_PHC
AtheroGenics_NN
,_,
Inc._NN
for_PIN
initial_JJ
consideration_NOMZ
of_PIN
$_$
41m_CD
,_,
$_$
10m_CD
and_CC
$_$
50m_CD
respectively_RB
._.
The_DT
transactions_NOMZ
were_VBD [PASS]
completed_VBN
in_PIN
January_NN
2006_CD
._.
All_QUAN
the_DT
collaboration_NOMZ
agreements_NOMZ
have_VPRT [PEAS]
deferred_VBN
consideration_NOMZ
obligations_NOMZ
,_,
dependent_JJ
upon_PIN
particular_JJ
milestone_NN
events_NN
._.
AstraZeneca_NN
also_RB
entered_VBD
into_PIN
an_DT
agreement_NOMZ
in_PIN
December_NN
2005_CD
to_TO
acquire_VB
the_DT
total_JJ
share_NN
capital_NN
of_PIN
KuDOS_NN
Pharmaceuticals_NN
Limited_NN
for_PIN
$_$
210m_CD
._.
The_DT
transaction_NOMZ
was_VBD [PASS]
completed_VBN
in_PIN
January_NN
2006_CD
._.
Arrangements_NOMZ
with_PIN
Merck_NN
Introduction_NOMZ
In_PIN
1982_CD
,_,
Astra_NN
AB_NN
set_VBD
up_RP
a_DT
joint_JJ
venture_NN
with_PIN
Merck_NN
&_CC
Co._NN
._.
Inc._NN
for_PIN
the_DT
purposes_NN
of_PIN
selling_GER
,_,
marketing_GER
and_CC
distributing_VBG
certain_JJ
Astra_NN
products_NN
in_PIN
the_DT
US_FPP1
._.
In_PIN
1998_CD
,_,
this_DEMO
joint_JJ
venture_NN
was_VBD [PASS]
restructured_VBN
the_DT
Restructuring_GER
._.
Under_IN
the_DT
agreements_NOMZ
relating_VBG [WZPRES]
to_PIN
the_DT
Restructuring_GER
the_DT
Agreements_NOMZ
,_,
a_DT
US_FPP1
limited_JJ
partnership_NN
was_VBD [PASS]
formed_VBN
,_,
in_PIN
which_WDT [PIRE]
Merck_NN
is_VPRT [BEMA]
the_DT
limited_JJ
partner_NN
and_PHC
AstraZeneca_NN
is_VPRT [BEMA]
the_DT
general_JJ
partner_NN
,_,
and_ANDC
AstraZeneca_NN
obtained_VBD
control_NN
of_PIN
the_DT
joint_JJ
ventures_NN
business_NOMZ
subject_NN
to_PIN
certain_JJ
limited_JJ
partner_NN
and_CC
other_JJ
rights_NN
held_VBN [PRIV] [WZPAST]
by_PIN
Merck_NN
and_CC
its_PIT
affiliates_NN
._.
These_DEMO
rights_NN
provide_VPRT
Merck_NN
with_PIN
safeguards_NN
over_IN
the_DT
activities_NOMZ
of_PIN
the_DT
partnership_NN
and_PHC
place_NN
limitations_NOMZ
on_PIN
AstraZenecas_NN
commercial_JJ
freedom_NN
to_TO
operate_VB
._.
The_DT
Agreements_NOMZ
provide_VB
for_PIN
:_:
Annual_JJ
contingent_JJ
payments_NOMZ
._.
A_DT
payment_NOMZ
to_PIN
Merck_NN
in_PIN
the_DT
event_NN
of_PIN
a_DT
business_NOMZ
combination_NOMZ
between_PIN
Astra_NN
and_CC
a_DT
third_JJ
party_NN
in_PIN
order_NN
for_PIN
Merck_NN
to_TO
relinquish_VB
certain_JJ
claims_NN
to_PIN
that_DEMO
third_JJ
partys_NN
products_NN
._.
Termination_NOMZ
arrangements_NOMZ
which_WDT [WHOBJ]
,_,
if_COND
and_ANDC
when_RB
triggered_VBN
,_,
cause_NN
Merck_NN
to_TO
relinquish_VB
its_PIT
interests_NN
in_PIN
AstraZenecas_NN
products_NN
and_PHC
activities_NOMZ
._.
These_DEMO
elements_NOMZ
are_VPRT [PASS]
discussed_VBN
in_PIN
further_JJ
detail_NN
below_PLACE
together_RB
with_PIN
a_DT
summary_NN
of_PIN
their_TPP3
accounting_GER
treatments_NOMZ
._.
Annual_JJ
contingent_JJ
payments_NOMZ
AstraZeneca_NN
makes_VPRT
ongoing_JJ
payments_NOMZ
to_PIN
Merck_NN
based_VBN [WZPAST]
on_PIN
sales_NN
of_PIN
certain_JJ
of_PIN
its_PIT
products_NN
in_PIN
the_DT
US_FPP1
the_DT
contingent_JJ
payments_NOMZ
on_PIN
the_DT
agreement_NOMZ
products_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
merger_NN
of_PIN
Astra_NN
and_PHC
Zeneca_NN
in_PIN
1999_CD
,_,
these_DEMO
contingent_JJ
payments_NOMZ
excluding_VBG [WZPRES]
those_DEMO
in_PIN
respect_NN
of_PIN
Prilosec_NN
and_PHC
Nexium_NN
can_POMD
not_XX0
be_VB [BEMA]
less_PRED
than_PIN
annual_JJ
minimum_NN
sums_NN
between_PIN
2002_CD
and_CC
2007_CD
ranging_VBG
from_PIN
$_$
125m_CD
to_TO
$_$
225m_CD
._.
AstraZenecas_NN
payments_NOMZ
have_VPRT [PEAS]
exceeded_VBN
the_DT
minimum_JJ
level_NN
in_PIN
2002_CD
to_PIN
2005_CD
and_CC
,_,
other_JJ
than_PIN
the_DT
possible_JJ
entry_NN
of_PIN
a_DT
generic_JJ
competitor_NN
to_PIN
Toprol-XL_NN
,_,
AstraZeneca_NN
has_VPRT
no_SYNE
reason_NN
to_TO
believe_VB [PRIV]
that_THVC
the_DT
annual_JJ
payments_NOMZ
in_PIN
the_DT
future_NN
will_PRMD
fall_VB
below_PLACE
the_DT
minimum_NN
obligations_NOMZ
._.
Payment_NOMZ
in_PIN
the_DT
event_NN
of_PIN
a_DT
business_NOMZ
combination_NOMZ
On_PIN
the_DT
merger_NN
of_PIN
Astra_NN
and_PHC
Zeneca_NN
,_,
a_DT
one-time_JJ
Lump_NN
Sum_NN
Payment_NOMZ
of_PIN
$_$
809m_CD
was_VBD [PASS]
triggered_VBN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
this_DEMO
payment_NOMZ
,_,
Merck_NN
relinquished_VBD
any_QUAN
claims_NN
it_PIT
may_POMD
have_VB [PEAS]
had_VBN
to_PIN
Zeneca_NN
products_NN
._.
Termination_NOMZ
arrangements_NOMZ
The_DT
Agreements_NOMZ
provided_VBD
for_PIN
arrangements_NOMZ
and_PHC
payments_NOMZ
under_IN
which_WDT
,_,
subject_JJ
to_PIN
the_DT
exercise_NN
of_PIN
certain_JJ
options_NOMZ
,_,
the_DT
rights_NN
and_PHC
interests_NN
in_PIN
AstraZenecas_NN
activities_NOMZ
and_PHC
products_NN
held_VBN [PRIV] [WZPAST]
by_PIN
Merck_NN
immediately_TIME
prior_RB
to_PIN
the_DT
merger_NN
would_PRMD
be_VB [PASS]
terminated_VBN
,_,
including_VBG
details_NN
of_PIN
:_:
The_DT
Advance_NN
Payment_NOMZ
The_DT
Partial_NN
Retirement_NOMZ
The_NN
First_NN
Option_NOMZ
and_CC
True-Up_JJ
The_DT
Loan_NN
Note_NN
Receivable_NN
The_NN
Second_NN
Option_NOMZ
Advance_NN
Payment_NOMZ
The_DT
merger_NN
between_PIN
Astra_NN
and_PHC
Zeneca_NN
triggered_VBD
the_DT
first_JJ
step_NN
in_PIN
the_DT
termination_NOMZ
arrangements_NOMZ
._.
Merck_NN
relinquished_VBD
all_QUAN
rights_NN
,_,
including_VBG
contingent_JJ
payments_NOMZ
on_PIN
future_JJ
sales_NN
,_,
to_PIN
potential_JJ
Astra_NN
products_NN
with_PIN
no_DT
existing_VBG
or_CC
pending_VBG
US_FPP1
patents_NN
at_PIN
the_DT
time_NN
of_PIN
the_DT
merger_NN
._.
As_CONJ
a_NULL
result_NULL
,_,
AstraZeneca_NN
now_TIME
has_VPRT
rights_NN
to_PIN
such_JJ
products_NN
and_CC
is_VPRT [PASS]
relieved_VBN
of_PIN
potential_JJ
obligations_NOMZ
to_PIN
Merck_NN
or_CC
restrictions_NOMZ
in_PIN
respect_NN
of_PIN
those_DEMO
products_NN
including_VBG [WZPRES]
annual_JJ
contingent_JJ
payments_NOMZ
,_,
affording_VBG
AstraZeneca_NN
substantial_JJ
freedom_NN
to_TO
exploit_VB
the_DT
products_NN
as_IN
it_PIT
sees_VPRT [PRIV]
fit_NN
._.
At_PIN
the_DT
time_NN
of_PIN
the_DT
merger_NN
,_,
the_DT
Advance_NN
Payment_NOMZ
was_VBD [PASS]
paid_VBN
._.
It_PIT
was_VBD [PASS]
calculated_VBN [PRIV]
as_IN
the_DT
then_RB
net_JJ
present_JJ
value_NN
of_PIN
$_$
2.8_CD
bn_NN
discounted_VBN [WZPAST]
from_PIN
2008_CD
to_PIN
the_DT
date_NN
of_PIN
merger_NN
at_PIN
a_DT
rate_NN
of_PIN
13_CD
%_NN
per_PIN
annum_NN
and_CC
amounted_VBD
to_TO
$_$
967m_CD
._.
It_PIT
is_VPRT [BEMA]
subject_PRED
to_PIN
a_DT
true-up_NN
in_PIN
2008_CD
,_,
as_IN
discussed_VBN
under_IN
First_NN
Option_NOMZ
and_CC
True-Up_JJ
below_PLACE
._.
Financial_NN
Statements_NOMZ
117_CD
25_CD
COMMITMENTS_NOMZ
AND_CC
CONTINGENT_JJ
LIABILITIES_NOMZ
CONTINUED_VBD
Partial_NN
Retirement_NOMZ
In_PIN
2008_CD
,_,
there_EX
will_PRMD
be_VB
a_DT
partial_JJ
retirement_NOMZ
of_PIN
Mercks_NN
limited_JJ
partnership_NN
interest_NN
by_PIN
payment_NOMZ
to_PIN
Merck_NN
of_PIN
an_DT
amount_NN
calculated_VBN [PRIV]
as_IN
a_DT
multiple_NN
of_PIN
the_DT
average_JJ
annual_JJ
contingent_JJ
payments_NOMZ
from_PIN
2005_CD
to_PIN
2007_CD
on_PIN
the_DT
relevant_JJ
products_NN
,_,
plus_PIN
$_$
750m_CD
._.
Upon_PIN
the_DT
Partial_NN
Retirement_NOMZ
,_,
Mercks_NN
rights_NN
in_PIN
respect_NN
of_PIN
certain_JJ
of_PIN
the_DT
agreement_NOMZ
products_NN
will_PRMD
end_VB
._.
The_DT
products_NN
covered_VBN [WZPAST]
by_PIN
the_DT
Partial_NN
Retirement_NOMZ
include_VPRT
Toprol-XL_NN
,_,
Pulmicort_NN
,_,
Rhinocort_NN
and_PHC
Symbicort_NN
,_,
the_DT
last_JJ
of_PIN
which_WDT [PIRE]
is_VPRT [PASS]
not_XX0
yet_RB
launched_VBN
in_PIN
the_DT
US_FPP1
and_CC
is_VPRT [BEMA]
subject_PRED
to_PIN
approval_NN
by_PIN
the_DT
FDA_NN
._.
First_NN
Option_NOMZ
and_CC
True-Up_JJ
In_PIN
2008_CD
,_,
a_DT
calculation_NOMZ
will_PRMD
be_VB [PASS]
made_VBN
of_PIN
the_DT
Appraised_NN
Value_NN
,_,
being_VBG [PRESP] [BEMA]
the_DT
net_JJ
present_JJ
value_NN
of_PIN
the_DT
future_JJ
contingent_JJ
payments_NOMZ
in_PIN
respect_NN
of_PIN
all_QUAN
agreement_NOMZ
products_NN
not_XX0
covered_VBN
by_PIN
the_DT
Partial_NN
Retirement_NOMZ
,_,
other_JJ
than_PIN
Prilosec_NN
and_PHC
Nexium_NN
._.
Payment_NOMZ
of_PIN
the_DT
Appraised_NN
Value_NN
to_PIN
Merck_NN
in_PIN
2008_CD
will_PRMD
take_VB
place_NN
only_DWNT
if_COND
Merck_NN
exercises_VPRT
the_DT
First_NN
Option_NOMZ
._.
Should_NEMD
Merck_NN
not_XX0
exercise_VB
this_DEMO
option_NOMZ
in_PIN
2008_CD
,_,
AstraZeneca_NN
may_POMD
exercise_VB
it_PIT
in_PIN
2010_CD
for_PIN
a_DT
sum_NN
equal_JJ
to_PIN
the_DT
2008_CD
Appraised_NN
Value_NN
._.
Contingent_JJ
payments_NOMZ
will_PRMD
continue_VB
from_PIN
2008_CD
to_PIN
2010_CD
if_COND
AstraZeneca_NN
exercises_NN
in_PIN
2010_CD
._.
Upon_PIN
exercise_NN
of_PIN
the_DT
First_NN
Option_NOMZ
Merck_NN
will_PRMD
relinquish_VB
its_PIT
rights_NN
over_IN
the_DT
agreement_NOMZ
products_NN
not_XX0
covered_VBN
by_PIN
the_DT
Partial_NN
Retirement_NOMZ
,_,
other_JJ
than_PIN
Nexium_NN
and_PHC
Prilosec_NN
._.
If_COND
neither_SYNE
Merck_NN
nor_SYNE
AstraZeneca_NN
exercises_VPRT
the_DT
option_NOMZ
,_,
the_DT
contingent_JJ
payment_NOMZ
arrangements_NOMZ
in_PIN
respect_NN
of_PIN
these_DEMO
agreement_NOMZ
products_NN
will_PRMD
continue_VB
as_RB
will_PRMD
AstraZenecas_NN
other_JJ
potential_JJ
obligations_NOMZ
and_PHC
restrictions_NOMZ
in_PIN
respect_NN
of_PIN
these_DEMO
products_NN
and_CC
the_DT
Appraised_NN
Value_NN
will_PRMD
not_XX0
be_VB [PASS]
paid_VBN
._.
Products_NN
covered_VBN [WZPAST]
by_PIN
the_DT
First_NN
Option_NOMZ
include_VPRT
Atacand_NN
,_,
Plendil_NN
and_CC
certain_JJ
compounds_NN
still_RB
in_PIN
development_NOMZ
,_,
including_VBG
Exanta_NN
._.
In_CONJ
addition_NULL
,_,
in_PIN
2008_CD
there_EX
will_PRMD
be_VB
a_DT
true-up_NN
of_PIN
the_DT
Advance_NN
Payment_NOMZ
._.
The_DT
true-up_JJ
amount_NN
will_PRMD
be_VB [PASS]
based_VBN
on_PIN
a_DT
multiple_NN
of_PIN
the_DT
average_JJ
annual_JJ
contingent_JJ
payments_NOMZ
from_PIN
2005_CD
to_PIN
2007_CD
in_PIN
respect_NN
of_PIN
all_QUAN
the_DT
agreement_NOMZ
products_NN
with_PIN
the_DT
exception_NOMZ
of_PIN
Prilosec_NN
and_PHC
Nexium_NN
subject_JJ
to_PIN
a_DT
minimum_NN
of_PIN
$_$
6.6_CD
bn_NN
,_,
plus_PIN
other_JJ
defined_VBN
amounts_NN
totalling_VBG [WZPRES]
$_$
912m_CD
._.
It_PIT
is_VPRT [SPAU] [BYPA]
then_RB
reduced_VBN
by_PIN
the_DT
Appraised_NN
Value_NN
whether_IN
paid_VBN
or_CC
not_XX0
,_,
the_DT
Partial_NN
Retirement_NOMZ
and_CC
the_DT
Advance_NN
Payment_NOMZ
at_PIN
its_PIT
undiscounted_JJ
amount_NN
of_PIN
$_$
2.8_CD
bn_NN
to_TO
determine_VB [SUAV] [PRIV]
the_DT
true-up_JJ
amount_NN
._.
The_DT
true-up_NN
will_PRMD
be_VB [PASS]
settled_VBN
in_PIN
2008_CD
irrespective_RB
of_PIN
whether_IN
the_DT
First_NN
Option_NOMZ
is_VPRT [PASS]
exercised_VBN
,_,
and_ANDC
this_DEMP
could_POMD
result_VB
in_PIN
a_DT
further_JJ
payment_NOMZ
by_PIN
AstraZeneca_NN
to_PIN
Merck_NN
or_CC
a_DT
payment_NOMZ
by_PIN
Merck_NN
to_PIN
AstraZeneca_NN
._.
Should_NEMD
Merck_NN
exercise_NN
the_DT
First_NN
Option_NOMZ
in_PIN
2008_CD
,_,
AstraZeneca_NN
will_PRMD
make_VB
payments_NOMZ
in_PIN
respect_NN
of_PIN
the_DT
Partial_NN
Retirement_NOMZ
,_,
the_DT
First_NN
Option_NOMZ
and_CC
the_DT
trueup_NN
totalling_VBG [WZPRES]
a_DT
minimum_NN
of_PIN
$_$
4.7_CD
bn_NN
._.
If_COND
AstraZeneca_NN
exercises_VPRT
the_DT
First_NN
Option_NOMZ
in_PIN
2010_CD
,_,
the_DT
combined_VBN
effect_NN
of_PIN
the_DT
amounts_NN
paid_VBN [WZPAST]
to_PIN
Merck_NN
in_PIN
2008_CD
and_CC
2010_CD
will_PRMD
total_VB
the_DT
same_JJ
amount_NN
._.
Loan_NN
Note_NN
Receivable_NN
Included_VBD
in_PIN
the_DT
assets_NN
and_PHC
liabilities_NOMZ
covered_VBN [WZPAST]
by_PIN
the_DT
Restructuring_GER
is_VPRT [BEMA]
a_DT
loan_NN
note_NN
receivable_NN
by_PIN
AstraZeneca_NN
from_PIN
Merck_NN
with_PIN
a_DT
face_NN
value_NN
of_PIN
$_$
1.4_CD
bn_NN
._.
In_PIN
2008_CD
,_,
at_PIN
the_DT
same_JJ
time_NN
as_IN
the_DT
settlement_NOMZ
of_PIN
the_DT
Partial_NN
Retirement_NOMZ
and_CC
the_DT
true-up_NN
,_,
Merck_NN
will_PRMD
settle_VB
the_DT
loan_NN
note_NN
receivable_NN
by_PIN
paying_VBG
AstraZeneca_NN
$_$
1.4_CD
bn_NN
._.
Second_JJ
Option_NOMZ
A_DT
Second_JJ
Option_NOMZ
exists_VPRT
whereby_OSUB
AstraZeneca_NN
has_VPRT
the_DT
option_NOMZ
to_TO
re-purchase_VB
Mercks_NN
interests_NN
in_PIN
Prilosec_NN
and_PHC
Nexium_NN
in_PIN
the_DT
US_FPP1
._.
This_DEMO
option_NOMZ
is_VPRT [BEMA]
exercisable_PRED
by_PIN
AstraZeneca_NN
two_CD
years_NN
after_IN
the_DT
exercise_NN
of_PIN
the_DT
First_NN
Option_NOMZ
,_,
whether_IN
the_DT
First_NN
Option_NOMZ
is_VPRT [PASS]
exercised_VBN
in_PIN
either_DT
2008_CD
or_CC
2010_CD
._.
Exercise_NN
of_PIN
the_DT
Second_JJ
Option_NOMZ
by_PIN
AstraZeneca_NN
at_PIN
a_DT
later_TIME
date_NN
is_VPRT [SPAU] [PASS]
also_RB
provided_VBN
for_PIN
in_PIN
2017_CD
or_CC
if_COND
combined_VBN
annual_JJ
sales_NN
of_PIN
the_DT
two_CD
products_NN
fall_VPRT
below_PLACE
a_DT
minimum_JJ
amount_NN
provided_VBN
,_,
in_PIN
each_QUAN
case_NN
,_,
that_THVC
the_DT
First_NN
Option_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
exercised_VBN
._.
The_DT
exercise_NN
price_NN
for_PIN
the_DT
Second_JJ
Option_NOMZ
is_VPRT [BEMA]
the_DT
net_JJ
present_JJ
value_NN
of_PIN
the_DT
future_JJ
annual_JJ
contingent_JJ
payments_NOMZ
on_PIN
Prilosec_NN
and_PHC
Nexium_NN
as_IN
determined_VBN [SUAV] [PRIV]
at_PIN
the_DT
time_NN
of_PIN
exercise_NN
._.
If_COND
the_DT
Second_JJ
Option_NOMZ
is_VPRT [PASS]
exercised_VBN
,_,
Merck_NN
will_PRMD [SPAU]
then_RB
have_VB [PEAS]
relinquished_VBN
all_QUAN
its_PIT
interests_NN
in_PIN
the_DT
partnership_NN
and_CC
the_DT
agreement_NOMZ
products_NN
including_VBG [WZPRES]
rights_NN
to_PIN
contingent_JJ
payments_NOMZ
._.
General_NN
The_NN
precise_JJ
amount_NN
and_PHC
timing_NN
of_PIN
settlements_NOMZ
with_PIN
Merck_NN
under_IN
the_DT
Partial_NN
Retirement_NOMZ
,_,
the_DT
First_NN
Option_NOMZ
and_CC
the_DT
true-up_NN
can_POMD
not_XX0
be_VB [PASS]
determined_VBN [SUAV] [PRIV]
at_PIN
this_DEMO
time_NN
._.
Various_JJ
components_NN
of_PIN
the_DT
calculations_NOMZ
are_VPRT [PASS]
based_VBN
,_,
in_PIN
part_NN
,_,
on_PIN
net_JJ
sales_NN
between_PIN
2005_CD
and_CC
2007_CD
and_CC
on_PIN
forecasted_JJ
performance_NN
beyond_IN
2007_CD
,_,
and_ANDC
payment_NOMZ
of_PIN
the_DT
First_NN
Option_NOMZ
is_VPRT [BEMA]
contingent_PRED
upon_PIN
Merck_NN
or_CC
AstraZeneca_NN
exercising_VBG [WZPRES]
the_DT
First_NN
Option_NOMZ
._.
Similarly_CONJ
,_,
the_DT
timing_NN
and_PHC
amount_NN
of_PIN
the_DT
Second_JJ
Option_NOMZ
can_POMD
not_XX0
be_VB [PASS]
determined_VBN [SUAV] [PRIV]
at_PIN
this_DEMO
time_NN
._.
With_PIN
the_DT
exception_NOMZ
of_PIN
the_DT
interests_NN
in_PIN
Nexium_NN
and_PHC
Prilosec_NN
,_,
the_DT
total_NN
of_PIN
the_DT
payments_NOMZ
yet_RB
to_TO
be_VB [PASS]
made_VBN
under_IN
the_DT
termination_NOMZ
arrangements_NOMZ
is_VPRT [PASS]
based_VBN
,_,
in_PIN
part_NN
,_,
on_PIN
the_DT
contingent_JJ
payments_NOMZ
made_VBN [WZPAST]
in_PIN
2005_CD
to_PIN
2007_CD
subject_JJ
to_PIN
the_DT
minimum_NN
amount_NN
and_CC
is_VPRT [BEMA]
likely_PRED
to_TO
be_VB [SPAU] [BYPA]
substantially_RB
driven_VBN
by_PIN
the_DT
sales_NN
of_PIN
Toprol-XL_NN
,_,
Pulmicort_NN
,_,
Rhinocort_NN
and_PHC
Atacand_NN
._.
However_CONJ
,_,
AstraZeneca_NN
anticipates_VPRT [PRIV]
that_THVC
the_DT
benefits_NN
that_TSUB
accrue_VPRT
under_IN
all_QUAN
the_DT
termination_NOMZ
arrangements_NOMZ
arise_VB
:_:
Currently_NN
,_,
from_PIN
the_DT
substantial_JJ
freedom_NN
over_IN
products_NN
acquired_VBN
or_CC
discovered_VBN [PRIV]
post-merger_NN
._.
On_PIN
occurrence_NN
of_PIN
each_QUAN
stage_NN
of_PIN
such_JJ
arrangements_NOMZ
,_,
from_PIN
enhanced_JJ
contributions_NOMZ
from_PIN [STPR]
,_,
and_ANDC
substantial_JJ
freedom_NN
over_IN
,_,
those_DEMO
products_NN
that_TSUB
have_VPRT [SPAU] [PEAS]
already_RB
been_VBN [PASS]
launched_VBN
for_CONJ
example_NULL
,_,
Rhinocort_NN
and_PHC
Atacand_NN
,_,
those_DEMO
that_DEMP
are_VPRT [BEMA]
due_PRED
to_TO
be_VB [PASS]
launched_VBN
in_PIN
the_DT
US_FPP1
in_CONJ
particular_NULL
,_,
Symbicort_NN
,_,
subject_JJ
to_PIN
approval_NN
by_PIN
the_DT
FDA_NN
and_CC
those_DEMO
that_DEMP
are_VPRT [BEMA]
in_PIN
development_NOMZ
._.
Benefits_NN
include_VPRT
relief_NN
from_PIN
contingent_JJ
payments_NOMZ
,_,
anticipated_VBN [PRIV]
cost_NN
savings_GER
from_PIN
cessation_NOMZ
of_PIN
manufacturing_VBG
arrangements_NOMZ
and_CC
other_JJ
cost_NN
efficiencies_NN
together_RB
with_PIN
the_DT
strategic_JJ
advantages_NN
of_PIN
increased_VBN
freedom_NN
to_TO
operate_VB
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
118_CD
Form_NN
20-F_JJ
Information_NOMZ
2005_CD
NOTES_NN
TO_PIN
THE_DT
FINANCIAL_NN
STATEMENTS_NOMZ
CONTINUED_VBD
25_CD
COMMITMENTS_NOMZ
AND_CC
CONTINGENT_JJ
LIABILITIES_NOMZ
CONTINUED_VBD
Accounting_GER
treatments_NOMZ
Annual_JJ
contingent_NN
payments_NOMZ
:_:
The_DT
annual_JJ
contingent_JJ
payments_NOMZ
on_PIN
agreement_NOMZ
products_NN
are_VPRT [PASS]
expensed_VBN
as_IN
incurred_VBN
._.
Payment_NOMZ
in_PIN
the_DT
event_NN
of_PIN
a_DT
business_NOMZ
combination_NOMZ
:_:
The_DT
Lump_NN
Sum_NN
Payment_NOMZ
was_VBD [PASS]
expensed_VBN
at_PIN
the_DT
point_NN
of_PIN
merger_NN
since_OSUB
it_PIT
caused_VBD
no_SYNE
incremental_JJ
benefits_NN
over_IN
the_DT
prior_JJ
years_NN
aggregate_JJ
Astra_NN
and_PHC
Zeneca_NN
performance_NN
to_TO
accrue_VB
to_PIN
the_DT
merged_JJ
AstraZeneca_NN
entity_NOMZ
._.
Termination_NOMZ
arrangements_NOMZ
:_:
AstraZeneca_NN
considers_VPRT [PRIV]
that_THVC
the_DT
termination_NOMZ
arrangements_NOMZ
described_VBN
above_PLACE
represent_VPRT
the_DT
acquisition_NOMZ
,_,
in_PIN
stages_NN
,_,
of_PIN
Mercks_NN
interests_NN
in_PIN
the_DT
partnership_NN
and_PHC
agreement_NOMZ
products_NN
including_VBG [WZPRES]
Mercks_NN
rights_NN
to_PIN
contingent_JJ
payments_NOMZ
and_CC
depend_VB
,_,
in_PIN
part_NN
,_,
on_PIN
the_DT
exercise_NN
of_PIN
the_DT
First_NN
and_PHC
Second_NN
Options_NOMZ
._.
The_DT
effects_NN
will_PRMD [SPAU]
only_DWNT
be_VB [PASS]
reflected_VBN [PRIV]
in_PIN
the_DT
Financial_NN
Statements_NOMZ
as_IN
these_DEMO
stages_NN
are_VPRT [PASS]
reached_VBN
._.
If_COND
and_ANDC
when_RB
all_QUAN
such_JJ
payments_NOMZ
are_VPRT [PASS]
made_VBN
,_,
AstraZeneca_NN
will_PRMD
have_VB
unencumbered_JJ
discretion_NOMZ
in_PIN
its_PIT
operations_NOMZ
in_PIN
the_DT
US_FPP1
market_NN
._.
The_DT
Advance_NN
Payment_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
accounted_VBN
for_PIN
as_IN
an_DT
intangible_JJ
asset_NN
and_CC
is_VPRT
being_VBG [PASS]
amortised_VBN
over_IN
20_CD
years_NN
._.
This_DEMO
approach_NN
reflects_VPRT [PRIV]
the_DT
fact_NN
that_DEMP
,_,
under_IN
the_DT
Agreements_NOMZ
,_,
AstraZeneca_NN
has_VPRT [PEAS]
acquired_VBN
rights_NN
relieving_VBG [WZPRES]
it_PIT
of_PIN
potential_JJ
obligations_NOMZ
or_CC
restrictions_NOMZ
in_PIN
respect_NN
of_PIN
Astra_NN
products_NN
with_PIN
no_DT
existing_VBG
or_CC
pending_VBG
patents_NN
at_PIN
the_DT
time_NN
of_PIN
merger_NN
._.
Although_CONC
these_DEMO
rights_NN
apply_VPRT
in_PIN
perpetuity_NOMZ
,_,
the_DT
period_NN
of_PIN
amortisation_NOMZ
of_PIN
20_CD
years_NN
has_VPRT [PEAS]
been_VBN [PASS]
chosen_VBN
to_TO
reflect_VB [PRIV]
the_DT
typical_JJ
timescale_NN
of_PIN
development_NOMZ
and_PHC
marketing_GER
of_PIN
a_DT
product_NN
._.
The_DT
payments_NOMZ
under_IN
the_DT
Partial_NN
Retirement_NOMZ
,_,
the_DT
First_NN
Option_NOMZ
and_PHC
true-up_NN
and_CC
the_DT
Second_JJ
Option_NOMZ
will_PRMD
be_VB [PASS]
accounted_VBN
for_PIN
under_IN
the_DT
extant_JJ
guidance_NN
when_RB
they_TPP3
are_VPRT [PASS]
paid_VBN
,_,
with_PIN
allocations_NOMZ
to_PIN
intangibles_NN
and_PHC
goodwill_NN
,_,
as_IN
appropriate_JJ
._.
If_COND
Merck_NN
exercises_VPRT
the_DT
First_NN
Option_NOMZ
in_PIN
2008_CD
,_,
the_DT
net_JJ
minimum_NN
payment_NOMZ
to_TO
be_VB [PASS]
made_VBN
to_PIN
Merck_NN
,_,
being_VBG [PRESP] [BEMA]
the_DT
combined_VBN
payments_NOMZ
of_PIN
$_$
4.7_CD
bn_NN
less_JJ
the_DT
repayment_NOMZ
of_PIN
the_DT
loan_NN
note_NN
of_PIN
$_$
1.4_CD
bn_NN
,_,
would_PRMD
be_VB
$_$
3.3_CD
bn_NN
._.
In_PIN
accounting_GER
for_PIN
the_DT
Restructuring_GER
in_PIN
1998_CD
,_,
the_DT
loan_NN
note_NN
was_VBD [PASS]
included_VBN
in_PIN
the_DT
determination_NOMZ
of_PIN
the_DT
fair_JJ
values_NN
of_PIN
the_DT
assets_NN
and_PHC
liabilities_NOMZ
to_TO
be_VB [PASS]
acquired_VBN
._.
At_PIN
that_DEMO
time_NN
,_,
the_DT
loan_NN
note_NN
was_VBD [PASS]
ascribed_VBN
a_DT
fair_JJ
value_NN
of_PIN
zero_CD
on_PIN
acquisition_NOMZ
and_CC
on_PIN
the_DT
balance_NN
sheet_NN
because_CAUS
it_PIT
was_VBD [PASS]
estimated_VBN [PRIV]
that_THVC
the_DT
net_JJ
minimum_NN
payment_NOMZ
of_PIN
$_$
3.3_CD
bn_NN
equated_VBN [WZPAST]
to_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
rights_NN
to_TO
be_VB [PASS]
acquired_VBN
under_IN
the_DT
Partial_NN
Retirement_NOMZ
,_,
true-up_NN
and_CC
First_JJ
Option_NOMZ
._.
Ongoing_JJ
monitoring_GER
of_PIN
the_DT
projected_VBN
payments_NOMZ
to_PIN
Merck_NN
and_CC
the_DT
value_NN
to_PIN
AstraZeneca_NN
of_PIN
the_DT
related_JJ
rights_NN
takes_VPRT
full_JJ
account_NN
of_PIN
changing_VBG
business_NOMZ
circumstances_NN
and_CC
the_DT
range_NN
of_PIN
possible_JJ
outcomes_NN
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
the_DT
payments_NOMZ
to_TO
be_VB [PASS]
made_VBN
to_PIN
Merck_NN
are_VPRT [BYPA]
covered_VBN
by_PIN
the_DT
economic_JJ
benefits_NN
expected_VBN [PRIV]
to_TO
be_VB [PASS]
realized_VBN [PRIV]
._.
Should_NEMD
the_DT
monitoring_GER
reveal_VPRT [PRIV]
that_THVC
these_DEMO
payments_NOMZ
exceed_VPRT
the_DT
economic_JJ
benefits_NN
expected_VBN [PRIV]
to_TO
be_VB [PASS]
realized_VBN [PRIV]
,_,
a_DT
provision_NN
for_PIN
an_DT
onerous_JJ
contract_NN
would_PRMD
be_VB [PASS]
recognized_VBN [PRIV]
._.
Environmental_JJ
costs_NN
and_PHC
liabilities_NOMZ
The_DT
Groups_NN
expenditure_NN
on_PIN
environmental_JJ
protection_NOMZ
,_,
including_VBG [PRESP]
both_DT
capital_NN
and_PHC
revenue_NN
items_NN
,_,
relates_VPRT
to_PIN
costs_NN
which_WDT [WHSUB]
are_VPRT [BEMA]
necessary_PRED
for_PIN
implementing_VBG
internal_JJ
systems_NN
and_PHC
programs_NN
and_CC
meeting_VBG
legal_JJ
and_PHC
regulatory_JJ
requirements_NOMZ
for_PIN
processes_NN
and_PHC
products_NN
._.
They_TPP3
are_VPRT [BEMA]
an_DT
integral_JJ
part_NN
of_PIN
normal_JJ
ongoing_JJ
expenditure_NN
for_PIN
carrying_VBG
out_PIN
the_DT
Groups_NN
research_NN
,_,
manufacturing_GER
and_CC
commercial_JJ
operations_NOMZ
and_CC
are_VPRT [PASS]
not_XX0
separated_VBN
from_PIN
overall_JJ
operating_GER
and_PHC
development_NOMZ
costs_NN
._.
There_EX
are_VPRT
no_DT
known_VBN [PRIV]
changes_NN
in_PIN
legal_JJ
,_,
regulatory_JJ
or_CC
other_JJ
requirements_NOMZ
resulting_VBG [WZPRES]
in_PIN
material_NN
changes_NN
to_PIN
the_DT
levels_NN
of_PIN
expenditure_NN
for_PIN
2003_CD
,_,
2004_CD
or_CC
2005_CD
._.
In_CONJ
addition_NULL
to_PIN
expenditure_NN
for_PIN
meeting_GER
current_JJ
and_CC
foreseen_VBN
environmental_JJ
protection_NOMZ
requirements_NOMZ
,_,
the_DT
Group_NN
incurs_VPRT
costs_NN
in_PIN
investigating_VBG
and_PHC
cleaning_VBG
up_RP
land_NN
and_PHC
groundwater_NN
contamination_NOMZ
._.
In_CONJ
particular_NULL
,_,
AstraZeneca_NN
and_CC
or_CC
its_PIT
affiliates_NN
have_VPRT
environmental_JJ
liabilities_NOMZ
at_PIN
some_QUAN
currently_RB
or_CC
formerly_TIME
owned_VBN
,_,
leased_VBN
and_CC
third_JJ
party_NN
sites_NN
._.
In_PIN
the_DT
US_FPP1
,_,
the_DT
AstraZeneca_NN
affiliate_NN
,_,
Zeneca_NN
Inc._NN
and_CC
or_CC
its_PIT
indemnitees_NN
,_,
have_VPRT [PEAS]
been_VBN [PASS]
named_VBN
as_IN
potentially_RB
responsible_JJ
parties_NN
PRPS_NN
or_CC
defendants_NN
at_PIN
approximately_RB
14_CD
sites_NN
where_RB
Zeneca_NN
Inc._NN
is_VPRT [BEMA]
likely_PRED
to_TO
incur_VB
future_JJ
investigation_NOMZ
,_,
remediation_NOMZ
or_CC
operation_NOMZ
and_PHC
maintenance_NN
costs_NN
under_IN
federal_JJ
or_CC
state_NN
,_,
statutory_JJ
or_CC
common_JJ
law_NN
environmental_JJ
liability_NOMZ
allocations_NOMZ
schemes_NN
._.
Similarly_CONJ
,_,
the_DT
AstraZeneca_NN
affiliate_NN
,_,
Stauffer_NN
Management_NOMZ
Company_NN
LLC_NN
SMC_NN
,_,
which_WDT [SERE]
was_VBD [PASS]
established_VBN [PRIV]
in_PIN
1987_CD
to_TO
own_VB
and_PHC
manage_VB
certain_JJ
assets_NN
of_PIN
Stauffer_NN
Chemical_NN
Company_NN
acquired_VBD
that_DEMO
year_NN
,_,
and_ANDC
or_CC
its_PIT
indemnitees_NN
,_,
have_VPRT [PEAS]
been_VBN [PASS]
named_VBN
as_IN
PRPS_NN
or_CC
defendants_NN
at_PIN
approximately_RB
32_CD
sites_NN
where_RB
SMC_NN
is_VPRT [BEMA]
likely_PRED
to_TO
incur_VB
future_JJ
investigation_NOMZ
,_,
remediation_NOMZ
or_CC
operation_NOMZ
and_PHC
maintenance_NN
costs_NN
under_IN
federal_JJ
or_CC
state_NN
,_,
statutory_JJ
or_CC
common_JJ
law_NN
environmental_JJ
liability_NOMZ
allocations_NOMZ
schemes_NN
._.
In_PIN
Europe_NN
and_CC
other_JJ
parts_NN
of_PIN
the_DT
world_NN
outside_PLACE
the_DT
US_FPP1
,_,
AstraZeneca_NN
is_VPRT [BEMA]
likely_PRED
to_TO
incur_VB
costs_NN
at_PIN
three_CD
currently_RB
owned_VBN
sites_NN
and_CC
has_VPRT [PEAS]
given_VBN
indemnities_NOMZ
to_PIN
third_JJ
parties_NN
in_PIN
respect_NN
of_PIN
approximately_RB
45_CD
other_JJ
sites_NN
._.
These_DEMO
environmental_JJ
liabilities_NOMZ
arise_VPRT
almost_DWNT
entirely_AMP
from_PIN
legacy_NN
operations_NOMZ
that_TSUB
are_VPRT
not_XX0
part_NN
of_PIN
our_FPP1
current_JJ
pharmaceuticals_NN
business_NOMZ
and_CC
,_,
at_PIN
most_EMPH
of_PIN
these_DEMO
sites_NN
,_,
remediation_NOMZ
,_,
where_RB
required_VBN [SUAV]
,_,
is_VPRT [SPAU] [PASS]
either_RB
completed_VBN
or_CC
nearing_VBG
completion_NOMZ
._.
In_PIN
the_DT
aggregate_NN
,_,
however_CONJ
,_,
expenditure_NN
on_PIN
clean_JJ
up_RB
and_CC
monitoring_GER
is_VPRT [BEMA]
likely_PRED
to_TO
be_VB [PASS]
required_VBN [SUAV]
._.
AstraZeneca_NN
has_VPRT [PEAS]
made_VBN
provisions_NN
for_PIN
the_DT
estimated_VBN [PRIV]
costs_NN
of_PIN
future_JJ
environmental_JJ
investigation_NOMZ
,_,
remediation_NOMZ
and_PHC
operation_NOMZ
and_PHC
maintenance_NN
activity_NOMZ
beyond_IN
normal_JJ
ongoing_JJ
expenditure_NN
for_PIN
maintaining_VBG [PUBV]
the_DT
Groups_NN
R&D_NN
and_CC
manufacturing_VBG
capacity_NOMZ
and_PHC
product_NN
ranges_NN
where_RB
a_DT
present_JJ
obligation_NOMZ
exists_VPRT
,_,
it_PIT
is_VPRT [BEMA]
probable_PRED
that_THAC
such_JJ
costs_NN
will_PRMD
be_VB [PASS]
incurred_VBN
,_,
and_ANDC
they_TPP3
can_POMD
be_VB [PASS]
estimated_VBN [PRIV]
reliably_RB
._.
With_PIN
respect_NN
to_PIN
such_JJ
estimated_VBN [PRIV]
,_,
future_JJ
costs_NN
,_,
there_EX
were_VBD
provisions_NN
at_PIN
31_CD
December_NN
2005_CD
in_PIN
the_DT
aggregate_NN
of_PIN
approximately_RB
$_$
80m_CD
,_,
of_PIN
which_WDT [PIRE]
approximately_RB
$_$
68m_CD
relates_VPRT
to_PIN
the_DT
US_FPP1
._.
These_DEMO
provisions_NN
do_VPRT
not_XX0
include_VB
possible_JJ
additional_JJ
costs_NN
that_TSUB
are_VPRT
not_XX0
currently_RB
probable_PRED
,_,
nor_SYNE
do_VB
these_DEMO
provisions_NN
include_VPRT
costs_NN
that_DEMP
,_,
by_PIN
agreement_NOMZ
,_,
will_PRMD
be_VB [BYPA]
borne_VBN
by_PIN
viable_JJ
third_JJ
party_NN
indemnitors_NN
._.
In_CONJ
addition_NULL
,_,
these_DEMO
provisions_NN
:_:
1_CD
include_VPRT
,_,
where_RB
appropriate_JJ
,_,
unasserted_JJ
claims_NN
where_RB
future_JJ
costs_NN
are_VPRT [BEMA]
nonetheless_CONJ
probable_PRED
at_PIN
owned_VBN
sites_NN
,_,
for_CONJ
example_NULL
:_:
2_CD
are_VPRT [PASS]
based_VBN
,_,
where_RB
applicable_JJ
,_,
on_PIN
liability_NOMZ
allocation_NOMZ
or_CC
cost_NN
sharing_GER
agreements_NOMZ
that_TOBJ
we_FPP1
believe_VPRT [PRIV]
are_VPRT [BEMA]
enforceable_PRED
against_PIN
viable_JJ
third_JJ
parties_NN
:_:
3_CD
reflect_VPRT [PRIV]
expected_VBN [PRIV]
insurance_NN
recoveries_NN
where_RB
an_DT
insurer_NN
has_VPRT [PEAS]
agreed_VBN [SUAV] [PUBV]
to_TO
provide_VB
an_DT
indemnity_NOMZ
:_:
and_ANDC
4_CD
typically_RB
cover_VPRT
a_DT
time_NN
period_NN
of_PIN
five_CD
years_NN
with_PIN
the_DT
exception_NOMZ
of_PIN
operation_NOMZ
and_PHC
maintenance_NN
activities_NOMZ
,_,
which_WDT [SERE]
can_POMD
last_VB
for_PIN
decades_NN
._.
AstraZeneca_NN
is_VPRT
not_XX0
presently_TIME
aware_PRED
of_PIN
any_QUAN
circumstances_NN
or_CC
uncertainties_NN
regarding_VBG [WZPRES]
the_DT
viability_NOMZ
of_PIN
liable_JJ
third_JJ
parties_NN
,_,
indemnitors_NN
or_CC
insurers_NN
that_TSUB
would_PRMD
cause_VB
these_DEMO
provisions_NN
to_TO
be_VB [PASS]
altered_VBN
._.
Financial_NN
Statements_NOMZ
119_CD
25_CD
COMMITMENTS_NOMZ
AND_CC
CONTINGENT_JJ
LIABILITIES_NOMZ
CONTINUED_VBD
It_PIT
is_VPRT [BEMA]
possible_PRED
that_THAC
the_DT
Company_NN
,_,
or_CC
its_PIT
affiliates_NN
,_,
could_POMD
incur_VB
future_JJ
environmental_JJ
costs_NN
beyond_IN
the_DT
extent_NN
of_PIN
our_FPP1
current_JJ
provisions_NN
._.
The_DT
extent_NN
of_PIN
such_JJ
possible_JJ
,_,
additional_JJ
costs_NN
is_VPRT [BEMA]
inherently_RB
difficult_PRED
to_TO
estimate_VB [PRIV]
due_JJ
to_PIN
a_DT
number_NN
of_PIN
factors_NN
,_,
including_VBG
,_,
but_CC
not_XX0
limited_VBN
to_TO
:_:
1_CD
the_DT
nature_NN
and_PHC
extent_NN
of_PIN
claims_NN
that_TSUB
may_POMD
be_VB [PASS]
asserted_VBN [PUBV]
in_PIN
the_DT
future_NN
:_:
2_CD
whether_IN
the_DT
Company_NN
or_CC
any_QUAN
of_PIN
its_PIT
affiliates_NN
has_VPRT
or_CC
will_PRMD
have_VB
any_QUAN
legal_JJ
obligation_NOMZ
with_PIN
respect_NN
to_TO
asserted_VBD [PUBV]
or_CC
unasserted_JJ
claims_NN
:_:
3_CD
the_DT
type_NN
of_PIN
remedial_JJ
action_NOMZ
,_,
if_COND
any_QUAN
,_,
that_DEMP
may_POMD
be_VB [PASS]
selected_VBN
at_PIN
sites_NN
where_RB
the_DT
remedy_NN
is_VPRT [PASS]
presently_TIME
not_XX0
known_VBN [PRIV]
:_:
4_LS
the_DT
potential_NN
for_PIN
recoveries_NN
from_PIN
or_CC
allocation_NOMZ
of_PIN
liability_NOMZ
to_PIN
third_JJ
parties_NN
:_:
and_ANDC
5_CD
the_DT
length_NN
of_PIN
time_NN
that_TOBJ
the_DT
environmental_JJ
investigation_NOMZ
,_,
remediation_NOMZ
and_PHC
liability_NOMZ
allocation_NOMZ
process_NN
can_POMD
take_VB
._.
Notwithstanding_CONJ
and_CC
subject_JJ
to_PIN
the_DT
foregoing_GER
,_,
it_PIT
is_VPRT [PASS]
estimated_VBN [PRIV]
that_THVC
potential_JJ
additional_JJ
loss_NN
for_PIN
future_JJ
environmental_JJ
investigation_NOMZ
,_,
remediation_NOMZ
and_CC
remedial_JJ
operation_NOMZ
and_PHC
maintenance_NN
activity_NOMZ
above_PLACE
and_CC
beyond_IN
our_FPP1
provisions_NN
could_POMD
be_VB
,_,
in_PIN
the_DT
aggregate_NN
,_,
in_PIN
the_DT
order_NN
of_PIN
$_$
20m_CD
to_TO
$_$
40m_CD
._.
Legal_JJ
proceedings_GER
AstraZeneca_NN
is_VPRT [PASS]
involved_VBN
in_PIN
various_JJ
legal_JJ
proceedings_GER
considered_VBN [PRIV]
typical_JJ
to_PIN
its_PIT
businesses_NOMZ
,_,
including_VBG
litigation_NOMZ
relating_VBG [WZPRES]
to_PIN
employment_NOMZ
,_,
product_NN
liability_NOMZ
,_,
commercial_JJ
disputes_NN
,_,
infringement_NOMZ
of_PIN
intellectual_JJ
property_NN
rights_NN
,_,
the_DT
validity_NOMZ
of_PIN
certain_JJ
patents_NN
,_,
and_ANDC
securities_NOMZ
law_NN
._.
The_DT
more_EMPH
significant_JJ
matters_NN
are_VPRT [PASS]
discussed_VBN
below_PLACE
._.
Crestor_NN
rosuvastatin_NN
AstraZeneca_NN
Pharmaceuticals_NN
LP_NN
and_CC
or_CC
AstraZeneca_NN
LP_NN
in_PIN
the_DT
US_FPP1
were_VBD [PASS]
served_VBN
with_PIN
two_CD
individual_JJ
lawsuits_NN
in_PIN
2004_CD
involving_VBG
alleged_JJ
injury_NN
in_PIN
association_NOMZ
with_PIN
the_DT
use_NN
of_PIN
Crestor_NN
._.
One_CD
of_PIN
these_DEMO
lawsuits_NN
has_VPRT [SPAU] [PEAS]
now_TIME
been_VBN [PASS]
dismissed_VBN
._.
In_CONJ
addition_NULL
,_,
a_DT
motion_NOMZ
for_PIN
authorisation_NOMZ
to_TO
institute_VB
a_DT
class_NN
action_NOMZ
and_CC
to_TO
be_VB [BEMA]
a_DT
representative_NN
was_VBD [PASS]
filed_VBN
in_PIN
Quebec_NN
,_,
Canada_NN
against_PIN
AstraZeneca_NN
PLC_NN
and_PHC
AstraZeneca_NN
Canada_NN
Inc._NN
._.
The_DT
petitioner_NN
claims_VPRT [PUBV]
alleged_JJ
injury_NN
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
use_NN
of_PIN
Crestor_NN
._.
During_PIN
2005_CD
,_,
AstraZeneca_NN
was_VBD [PASS]
served_VBN
with_PIN
five_CD
other_JJ
similar_JJ
complaints_NN
in_PIN
the_DT
US_FPP1
,_,
two_CD
of_PIN
which_WDT [PIRE]
were_VBD [SPAU] [PASS]
recently_TIME
dismissed_VBN
._.
AstraZeneca_NN
is_VPRT [SPAU]
vigorously_RB
defending_VBG
all_QUAN
the_DT
remaining_VBG
actions_NOMZ
._.
Diprivan_NN
propofol_NN
In_PIN
August_NN
2002_CD
,_,
AstraZeneca_NN
LP_NN
received_VBD
a_DT
letter_NN
from_PIN
ESI_NN
Lederle_NN
,_,
a_DT
division_NN
of_PIN
Wyeth_NN
,_,
informing_VBG
AstraZeneca_NN
of_PIN
Wyeths_NN
intention_NOMZ
to_TO
market_VB
a_DT
generic_JJ
version_NN
of_PIN
Diprivan_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
of_PIN
AstraZenecas_NN
patents_NN
covering_VBG [WZPRES]
the_DT
current_JJ
formulation_NOMZ
._.
AstraZeneca_NN
filed_VBD
a_DT
patent_NN
infringement_NOMZ
action_NOMZ
against_PIN
Wyeth_NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Southern_NN
District_NN
of_PIN
New_NN
York_NN
._.
Through_PIN
a_DT
series_NN
of_PIN
transactions_NOMZ
,_,
the_DT
holder_NN
of_PIN
the_DT
relevant_JJ
Abbreviated_NN
New_NN
Drug_NN
Application_NOMZ
and_CC
now_TIME
defendant_NN
in_PIN
AstraZenecas_NN
suit_NN
is_VPRT
Mayne_NN
Pharma_NN
USA_NN
Inc._NN
formerly_TIME
called_VBD
Faulding_GER
Pharmaceutical_NN
Co._NN
._.
Mayne_NN
responded_VBD
to_PIN
AstraZenecas_NN
complaint_NN
and_CC
filed_VBD
counterclaims_NN
alleging_VBG [PUBV] [WZPRES]
non-infringement_JJ
,_,
invalidity_NOMZ
and_PHC
unenforceability_NOMZ
._.
The_DT
trial_NN
,_,
post-trial_JJ
briefing_GER
and_PHC
closing_GER
arguments_NOMZ
took_VBD
place_NN
in_PIN
early_TIME
2005_CD
._.
In_PIN
November_NN
2005_CD
,_,
the_DT
court_NN
issued_VBD
its_PIT
decision_NN
finding_VBG [PRIV] [WZPRES]
the_DT
AstraZeneca_NN
patents_NN
to_TO
be_VB [BEMA]
valid_PRED
and_PHC
enforceable_PRED
and_CC
infringed_VBN
by_PIN
Maynes_NN
propofol_NN
product_NN
._.
The_DT
court_NN
has_VPRT [PEAS]
issued_VBN
an_DT
injunction_NOMZ
preventing_VBG [WZPRES]
the_DT
manufacture_NN
,_,
use_NN
,_,
sale_NN
and_PHC
offering_GER
for_PIN
sale_NN
in_PIN
the_DT
US_FPP1
of_PIN
Maynes_NN
propofol_NN
product_NN
._.
Mayne_NN
has_VPRT [PEAS]
filed_VBN
an_DT
appeal_NN
of_PIN
the_DT
courts_NN
findings_GER
to_PIN
the_DT
Federal_NN
Circuit_NN
Court_NN
of_PIN
Appeals_NN
._.
In_PIN
September_NN
2005_CD
,_,
AstraZeneca_NN
received_VBD
notification_NOMZ
from_PIN
Amphastar_NN
Pharmaceuticals_NN
Inc._NN
under_IN
section_NOMZ
505_CD
b_NN
2_CD
of_PIN
the_DT
US_FPP1
Food_NN
,_,
Drug_NN
and_PHC
Cosmetic_NN
Act_NN
that_DEMP
,_,
after_IN
approval_NN
by_PIN
the_DT
FDA_NN
,_,
it_PIT
intends_VPRT [SUAV]
to_TO
manufacture_VB
and_PHC
sell_VB
propofol_NN
in_PIN
the_DT
US_FPP1
prior_RB
to_PIN
the_DT
expiration_NOMZ
of_PIN
certain_JJ
of_PIN
AstraZenecas_NN
propofol-related_JJ
patents_NN
._.
Amphastar_NN
contends_VPRT [PUBV]
that_THVC
these_DEMO
patents_NN
would_PRMD
not_XX0
be_VB [BYPA]
infringed_VBN
by_PIN
such_JJ
manufacture_NN
and_PHC
sale_NN
._.
AstraZeneca_NN
did_VBD
not_XX0
file_VB
a_DT
patent_NN
infringement_NOMZ
complaint_NN
against_PIN
Amphastar_NN
._.
Exanta_NN
ximelagatran_NN
Four_CD
putative_NN
and_CC
essentially_RB
similar_JJ
securities_NOMZ
class_NN
actions_NOMZ
were_VBD [PASS]
filed_VBN
in_PIN
the_DT
US_FPP1
against_PIN
AstraZeneca_NN
PLC_NN
,_,
Hkan_NN
Mogren_NN
,_,
Sir_NN
Tom_NN
McKillop_NN
,_,
Jonathan_NN
Symonds_NN
and_PHC
Percy_NN
Barnevik_NN
between_PIN
January_NN
and_PHC
March_NN
2005_CD
._.
These_DEMO
actions_NOMZ
allege_VPRT [PUBV]
that_THVC
the_DT
defendants_NN
made_VBD
materially_RB
false_JJ
and_PHC
misleading_JJ
statements_NOMZ
regarding_VBG [WZPRES]
Exanta_NN
clinical_JJ
trials_NN
and_CC
the_DT
status_NN
of_PIN
the_DT
Exanta_NN
New_NN
Drug_NN
Application_NOMZ
in_PIN
the_DT
US_FPP1
._.
The_DT
cases_NN
purport_VPRT
to_TO
assert_VB [PUBV]
claims_NN
on_PIN
behalf_NN
of_PIN
purchasers_NN
of_PIN
AstraZeneca_NN
publicly_RB
traded_VBD
securities_NOMZ
during_PIN
the_DT
period_NN
2_CD
April_NN
2003_CD
to_PIN
11_CD
October_NN
2004_CD
under_IN
sections_NOMZ
10_CD
b_NN
and_CC
20_CD
a_DT
of_PIN
the_DT
Securities_NOMZ
Exchange_NN
Act_NN
of_PIN
1934_CD
and_CC
SEC_NN
Rule_NN
10b-5_JJ
._.
The_DT
cases_NN
were_VBD [BEMA]
all_QUAN
filed_VBN
in_PIN
federal_JJ
district_NN
courts_NN
one_CD
in_PIN
the_DT
District_NN
of_PIN
Massachusetts_NN
,_,
one_CD
in_PIN
the_DT
District_NN
of_PIN
Delaware_NN
and_CC
two_CD
in_PIN
the_DT
Southern_NN
District_NN
of_PIN
New_NN
York_NN
._.
The_DT
Delaware_NN
case_NN
was_VBD [PASS]
dismissed_VBN
voluntarily_RB
and_CC
the_DT
Massachusetts_NN
case_NN
has_VPRT [PEAS]
been_VBN [PASS]
transferred_VBN
to_PIN
the_DT
Southern_NN
District_NN
of_PIN
New_NN
York_NN
by_PIN
way_NN
of_PIN
stipulation_NOMZ
._.
The_DT
remaining_VBG
cases_NN
are_VPRT [BEMA]
likely_PRED
to_TO
be_VB [PASS]
consolidated_VBN
in_PIN
a_DT
single_JJ
action_NOMZ
in_PIN
New_NN
York_NN
._.
The_DT
defendants_NN
deny_VPRT [PUBV] [THATD]
the_DT
allegations_NOMZ
made_VBN [WZPAST]
in_PIN
the_DT
lawsuits_NN
and_CC
will_PRMD [SPAU]
vigorously_RB
defend_VB
the_DT
actions_NOMZ
._.
Iressa_NN
gefitinib_NN
During_PIN
2004_CD
and_CC
2005_CD
,_,
five_CD
claims_NN
have_VPRT [PEAS]
been_VBN [PASS]
filed_VBN
against_PIN
AstraZeneca_NN
KK_NN
in_PIN
Japan_NN
,_,
in_PIN
the_DT
Osaka_NN
and_PHC
Tokyo_NN
District_NN
Courts_NN
._.
In_PIN
four_CD
of_PIN
the_DT
claims_NN
,_,
it_PIT
is_VPRT [PASS]
alleged_VBN [PUBV]
that_THVC
Iressa_NN
caused_VBD
a_DT
fatal_JJ
incidence_NN
of_PIN
interstitial_JJ
lung_NN
disease_NN
ILD_NN
in_PIN
a_DT
Japanese_JJ
patient_NN
._.
In_PIN
the_DT
fifth_JJ
claim_NN
,_,
which_WDT [SERE]
did_VBD
not_XX0
involve_VB
a_DT
fatality_NOMZ
,_,
it_PIT
is_VPRT [PASS]
alleged_VBN [PUBV]
that_THVC
Iressa_NN
caused_VBD
an_DT
incidence_NN
of_PIN
ILD_NN
._.
AstraZeneca_NN
KK_NN
,_,
following_VBG
consultation_NOMZ
with_PIN
external_JJ
legal_JJ
advisers_NN
,_,
believes_VPRT [PRIV] [THATD]
the_DT
claims_NN
are_VPRT [BEMA]
without_PIN
merit_NN
and_CC
is_VPRT
defending_VBG
all_QUAN
of_PIN
the_DT
cases_NN
._.
ILD_NN
is_VPRT [BEMA]
a_DT
known_JJ
complication_NOMZ
of_PIN
lung_NN
disease_NN
,_,
including_VBG
advanced_JJ
lung_NN
cancer_NN
,_,
regardless_RB
of_PIN
treatment_NOMZ
._.
Losec_NN
Prilosec_NN
omeprazole_NN
In_PIN
2001_CD
,_,
AstraZeneca_NN
filed_VBD
suit_NN
in_PIN
the_DT
US_FPP1
against_PIN
Andrx_NN
Pharmaceuticals_NN
,_,
Inc._NN
for_PIN
infringement_NOMZ
of_PIN
a_DT
patent_NN
directed_VBD
to_PIN
a_DT
process_NN
for_PIN
making_VBG
an_DT
omeprazole_NN
formulation_NOMZ
the_DT
281_CD
patent_NN
._.
Andrx_NN
filed_VBD
counterclaims_NN
of_PIN
non-infringement_NOMZ
,_,
invalidity_NOMZ
and_PHC
unenforceability_NOMZ
for_PIN
inequitable_JJ
conduct_NN
during_PIN
prosecution_NOMZ
of_PIN
the_DT
281_CD
patent_NN
._.
Andrx_NN
also_RB
asserted_VBD [PUBV]
that_THVC
in_CONJ
addition_NULL
to_PIN
the_DT
281_CD
patent_NN
,_,
two_CD
other_JJ
formulation_NOMZ
patents_NN
,_,
the_DT
505_CD
and_CC
230_CD
patents_NN
,_,
were_VBD [BEMA]
unenforceable_PRED
for_PIN
alleged_JJ
litigation_NOMZ
misconduct_NN
by_PIN
AstraZeneca_NN
._.
Both_DT
parties_NN
sought_VBD
attorneys_NN
fees_NN
._.
In_PIN
May_POMD
2004_CD
,_,
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Southern_NN
District_NN
of_PIN
New_NN
York_NN
ruled_VBD [SUAV]
that_THVC
the_DT
281_CD
patent_NN
was_VBD [PASS]
infringed_VBN
,_,
but_CC
also_RB
ruled_VBD [SUAV]
that_THVC
the_DT
281_CD
patent_NN
was_VBD [BEMA]
invalid_PRED
._.
The_DT
court_NN
dismissed_VBD
Andrxs_NN
litigation_NOMZ
misconduct_NN
and_CC
other_JJ
counterclaims_NN
and_CC
affirmative_JJ
defences_NN
,_,
leaving_VBG
intact_JJ
the_DT
courts_NN
October_NN
2002_CD
decision_NN
finding_VBG [PRIV] [WZPRES]
the_DT
230_CD
and_CC
505_CD
patents_NN
not_XX0
invalid_JJ
and_CC
infringed_VBN
by_PIN
Andrx_NN
._.
The_DT
October_NN
2002_CD
decision_NN
was_VBD [PASS]
affirmed_VBN [PUBV]
in_PIN
all_QUAN
respects_NN
on_PIN
appeal_NN
in_PIN
December_NN
2003_CD
._.
The_DT
court_NN
entered_VBD
final_JJ
judgement_NOMZ
regarding_VBG [WZPRES]
the_DT
281_CD
patent_NN
in_PIN
July_NN
2004_CD
,_,
after_IN
determining_VBG [SUAV] [PRIV]
to_TO
stay_VB
the_DT
attorneys_NN
fees_NN
claims_NN
pending_VBG [WZPRES]
any_QUAN
appeals_NN
._.
Andrx_NN
has_VPRT [PEAS]
appealed_VBN
the_DT
judgement_NOMZ
and_PHC
AstraZeneca_NN
has_VPRT [PEAS]
cross-appealed_VBN
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
120_CD
Form_NN
20-F_JJ
Information_NOMZ
2005_CD
NOTES_NN
TO_PIN
THE_DT
FINANCIAL_NN
STATEMENTS_NOMZ
CONTINUED_VBD
25_CD
COMMITMENTS_NOMZ
AND_CC
CONTINGENT_JJ
LIABILITIES_NOMZ
CONTINUED_VBD
During_PIN
2000_CD
and_CC
2001_CD
,_,
AstraZeneca_NN
had_VBD [PEAS]
filed_VBN
suits_NN
against_PIN
Lek_NN
Pharmaceutical_NN
and_PHC
Chemical_NN
Company_NN
d._NN
d._NN
and_PHC
Lek_NN
Services_NN
USA_NN
,_,
Inc._NN
._.
Impax_NN
Laboratories_NN
Inc._NN
._.
Eon_NN
Labs_NN
Manufacturing_GER
Inc._NN
._.
Mylan_NN
Pharmaceuticals_NN
Inc._NN
._.
Apotex_NN
Corp_NN
,_,
Apotex_NN
,_,
Inc._NN
and_PHC
Torpharm_NN
,_,
Inc._NN
and_PHC
Zenith_NN
Goldline_NN
Pharmaceuticals_NN
,_,
Inc._NN
now_TIME
known_VBN [PRIV]
as_IN
IVAX_NN
Pharmaceuticals_NN
,_,
Inc._NN
._.
These_DEMO
suits_NN
followed_VBD
the_DT
filing_NN
of_PIN
Abbreviated_NN
New_NN
Drug_NN
Applica_NN
tions_NOMZ
by_PIN
these_DEMO
companies_NN
with_PIN
the_DT
FDA_NN
concerning_VBG [WZPRES]
the_DT
companies_NN
intention_NOMZ
to_PIN
market_NN
generic_JJ
omeprazole_NN
products_NN
in_PIN
the_DT
US_FPP1
._.
The_DT
basis_NN
for_PIN
the_DT
proceedings_GER
is_VPRT
that_DEMO
the_DT
actions_NOMZ
of_PIN
all_QUAN
the_DT
companies_NN
infringe_VPRT
the_DT
505_CD
and_CC
230_CD
formulation_NOMZ
patents_NN
relating_VBG [WZPRES]
to_PIN
omeprazole_NN
._.
The_DT
cases_NN
are_VPRT
proceeding_VBG
under_IN
the_DT
US_FPP1
Hatch-Waxman_NN
legislation_NOMZ
._.
The_DT
case_NN
against_PIN
IVAX_NN
was_VBD [PASS]
dismissed_VBN
without_PIN
prejudice_NN
shortly_TIME
after_IN
it_PIT
was_VBD [PASS]
filed_VBN
,_,
after_IN
IVAXwithdrew_NN
its_PIT
application_NOMZ
to_PIN
market_NN
generic_JJ
omeprazole_NN
._.
During_PIN
2003_CD
,_,
after_IN
Mylan_NN
commenced_VBD
commercial_JJ
sale_NN
of_PIN
its_PIT
product_NN
,_,
AstraZeneca_NN
filed_VBD
suit_NN
against_PIN
Laboratorios_NN
Esteve_NN
,_,
SA_NN
and_PHC
Esteve_NN
Quimica_NN
,_,
SA_NN
,_,
manufacturers_NN
of_PIN
the_DT
omeprazole_JJ
product_NN
to_TO
be_VB [PASS]
distributed_VBN
in_PIN
the_DT
US_FPP1
by_PIN
Mylan_NN
._.
In_PIN
2003_CD
and_CC
2004_CD
,_,
Lek_NN
,_,
Apotex_NN
and_PHC
Impax_NN
all_QUAN
began_VBD
commercial_JJ
sales_NN
of_PIN
their_TPP3
generic_JJ
omeprazole_NN
products_NN
._.
In_PIN
July_NN
2004_CD
,_,
Lek_NN
filed_VBD
a_DT
motion_NOMZ
for_PIN
summary_NN
judgement_NOMZ
of_PIN
noninfringement_NOMZ
._.
In_PIN
January_NN
2005_CD
,_,
AstraZeneca_NN
filed_VBD
suit_NN
against_PIN
Teva_NN
Pharmaceutical_NN
Industries_NN
Ltd._NN
and_PHC
Teva_NN
Pharmaceuticals_NN
USA_NN
,_,
Inc._NN
which_WDT [WHSUB]
are_VPRT
marketing_VBG
and_PHC
selling_VBG
Impaxs_NN
omeprazole_NN
products_NN
._.
The_DT
Teva_NN
case_NN
was_VBD [PASS]
stayed_VBN
in_PIN
June_NN
2005_CD
until_IN
liability_NOMZ
issues_NN
in_PIN
the_DT
Impax_NN
action_NOMZ
are_VPRT [PASS]
resolved_VBN [SUAV]
._.
AstraZeneca_NN
has_VPRT [PEAS]
made_VBN
claims_NN
for_PIN
damages_NN
against_PIN
each_QUAN
of_PIN
the_DT
selling_GER
defendants_NN
._.
Anti-trust_NN
and_CC
non-infringement_JJ
counterclaims_NN
have_VPRT [PEAS]
been_VBN [BYPA]
filed_VBN
by_PIN
Andrx_NN
,_,
Apotex_NN
Torpharm_NN
,_,
Impax_NN
,_,
Eon_NN
and_PHC
Lek_NN
._.
All_QUAN
defendants_NN
except_PIN
Lek_NN
have_VPRT [SPAU] [PEAS]
also_RB
raised_VBN
invalidity_NOMZ
and_PHC
unenforceability_NOMZ
counterclaims_NN
._.
The_DT
anti-trust_JJ
counterclaims_NN
,_,
as_RB
well_RB
as_IN
AstraZenecas_NN
claims_NN
for_PIN
damages_NN
,_,
have_VPRT [PEAS]
been_VBN [PASS]
stayed_VBN
pending_VBG
resolution_NOMZ
of_PIN
the_DT
patent_NN
liability_NOMZ
issues_NN
._.
The_DT
cases_NN
have_VPRT [PEAS]
been_VBN [PASS]
consolidated_VBN
for_PIN
discovery_NN
before_IN
,_,
or_CC
are_VPRT [SPAU] [PASS]
directly_RB
assigned_VBN
to_TO
,_,
Judge_NN
Jones_NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Southern_NN
District_NN
of_PIN
New_NN
York_NN
._.
All_QUAN
discovery_NN
in_PIN
these_DEMO
cases_NN
was_VBD [PASS]
completed_VBN
in_PIN
February_NN
2005_CD
._.
Briefing_GER
on_PIN
the_DT
summary_NN
judgement_NOMZ
motion_NOMZ
filed_VBN [WZPAST]
by_PIN
Lek_NN
and_CC
14_CD
additional_JJ
motions_NOMZ
for_PIN
summary_NN
judgement_NOMZ
was_VBD [PASS]
completed_VBN
in_PIN
July_NN
2005_CD
._.
All_QUAN
of_PIN
the_DT
defendants_NN
motions_NOMZ
for_PIN
summary_NN
judgement_NOMZ
were_VBD [PASS]
denied_VBN [PUBV]
in_PIN
January_NN
2006_CD
._.
In_PIN
July_NN
2005_CD
,_,
AstraZeneca_NN
filed_VBD
suit_NN
against_PIN
Ranbaxy_NN
Laboratories_NN
Ltd._NN
._.
Ranbaxy_NN
Inc._NN
and_PHC
Ranbaxy_NN
Pharmaceuticals_NN
,_,
Inc._NN
for_PIN
infringement_NOMZ
of_PIN
the505_CD
and_CC
230_CD
formulation_NOMZ
patents_NN
._.
The_DT
Ranbaxy_NN
case_NN
has_VPRT [PEAS]
been_VBN [PASS]
consolidated_VBN
with_PIN
the_DT
other_JJ
omeprazole_NN
patent_NN
cases_NN
for_PIN
pre-trial_JJ
purposes_NN
._.
Judge_NN
Jones_NN
has_VPRT [PEAS]
scheduled_VBN
a_DT
consolidated_JJ
bench_NN
trial_NN
to_TO
begin_VB
in_PIN
March_NN
2006_CD
._.
In_PIN
June_NN
and_PHC
July_NN
2004_CD
,_,
AstraZeneca_NN
applied_VBD
in_PIN
France_NN
for_PIN
injunctions_NOMZ
based_VBN [WZPAST]
on_PIN
its_PIT
omeprazole_NN
formulation_NOMZ
patent_NN
against_PIN
six_CD
companies_NN
for_PIN
marketing_GER
generic_JJ
omeprazole_NN
._.
In_PIN
August_NN
2004_CD
,_,
the_DT
applications_NOMZ
were_VBD [PASS]
rejected_VBN
at_PIN
first_JJ
instance_NN
._.
AstraZeneca_NN
appealed_VBD
this_DEMO
decision_NN
and_CC
in_PIN
March_NN
2005_CD
the_DT
applications_NOMZ
were_VBD [PASS]
rejected_VBN
on_PIN
appeal_NN
._.
In_PIN
May_POMD
2004_CD
,_,
AstraZeneca_NN
also_RB
started_VBD
legal_JJ
proceedings_GER
against_PIN
the_DT
same_JJ
companies_NN
for_PIN
infringement_NOMZ
of_PIN
its_PIT
omeprazole_NN
formulation_NOMZ
patent_NN
in_PIN
France_NN
._.
These_DEMO
proceedings_GER
have_VPRT [PEAS]
been_VBN [PASS]
consolidated_VBN
with_PIN
a_DT
case_NN
challenging_VBG [WZPRES]
the_DT
validity_NOMZ
of_PIN
the_DT
patent_NN
,_,
brought_VBN [PASTP]
by_PIN
one_CD
of_PIN
the_DT
companies_NN
against_PIN
AstraZeneca_NN
._.
No_SYNE
date_NN
has_VPRT [SPAU] [PEAS]
yet_RB
been_VBN [PASS]
set_VBN
for_PIN
a_DT
hearing_GER
._.
During_PIN
2000_CD
,_,
AstraZeneca_NN
was_VBD [PASS]
granted_VBN [SUAV] [THATD]
interlocutory_JJ
injunctions_NOMZ
based_VBN [WZPAST]
on_PIN
certain_JJ
of_PIN
AstraZenecas_NN
omeprazole_NN
patents_NN
against_PIN
the_DT
generic_JJ
company_NN
,_,
Scandinavian_NN
AB_NN
Scand_NN
Pharm_NN
,_,
in_PIN
Denmark_NN
and_PHC
Norway_NN
._.
In_PIN
October_NN
2001_CD
,_,
Oslo_NN
City_NOMZ
Court_NN
in_PIN
Norway_NN
confirmed_VBD [PUBV]
that_THVC
Scand_NN
Pharm_NN
had_VBD [PEAS]
infringed_VBN
AstraZenecas_NN
formulation_NOMZ
patent_NN
for_PIN
omeprazole_NN
._.
At_PIN
the_DT
same_JJ
time_NN
,_,
the_DT
court_NN
declared_VBD [PUBV]
AstraZenecas_NN
formulation_NOMZ
patent_NN
valid_JJ
._.
In_PIN
November_NN
2004_CD
,_,
these_DEMO
findings_GER
were_VBD [BYPA]
upheld_VBN
by_PIN
the_DT
Appeal_NN
Court_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
Norwegian_JJ
case_NN
,_,
Scand_NN
Pharm_NN
can_POMD
not_XX0
sell_VB
its_PIT
omeprazole_JJ
product_NN
in_PIN
Norway_NN
._.
Furthermore_CONJ
,_,
it_PIT
is_VPRT [SPAU] [PASS]
also_RB
prevented_VBN
from_PIN
selling_VBG
its_PIT
omeprazole_JJ
product_NN
in_PIN
Denmark_NN
pending_VBG [WZPRES]
the_DT
outcome_NN
of_PIN
the_DT
main_JJ
action_NOMZ
in_PIN
the_DT
Danish_JJ
case_NN
._.
If_COND
the_DT
final_JJ
decision_NN
in_PIN
this_DEMO
case_NN
is_VPRT [BEMA]
against_PIN
AstraZeneca_NN
,_,
Scand_NN
Pharm_NN
may_POMD
claim_VB [PUBV]
damages_NN
for_PIN
lost_VBN
sales_NN
due_JJ
to_PIN
the_DT
interlocutory_JJ
injunctions_NOMZ
._.
During_PIN
2003_CD
and_CC
2004_CD
,_,
AstraZeneca_NN
was_VBD [PASS]
denied_VBN [PUBV] [THATD]
interlocutory_JJ
injunctions_NOMZ
based_VBN [WZPAST]
on_PIN
certain_JJ
of_PIN
its_PIT
omeprazole_NN
patents_NN
against_PIN
Novartis_NN
Sverige_NN
AB_NN
and_CC
ratiopharm_JJ
AB_NN
in_PIN
Sweden_NN
and_PHC
Novartis_NN
Finland_NN
Oy_NN
and_CC
ratiopharm_JJ
Oy_NN
in_PIN
Finland_NN
._.
An_DT
interlocutory_JJ
injunction_NOMZ
against_PIN
Biochemie_NN
Novartis_NN
Healthcare_NN
A_NN
S_NN
was_VBD [PASS]
granted_VBN [SUAV]
in_PIN
Denmark_NN
during_PIN
2003_CD
,_,
based_VBN [PASTP]
on_PIN
AstraZenecas_NN
omeprazole_NN
formulation_NOMZ
patent_NN
._.
Also_RB
during_PIN
2003_CD
,_,
the_DT
District_NN
Court_NN
in_PIN
Norway_NN
found_VBD [PRIV]
that_THVC
the_DT
generic_JJ
omeprazole_NN
product_NN
marketed_VBN [WZPAST]
by_PIN
ratiopharm_JJ
AS_NN
did_VBD
not_XX0
infringe_VB
AstraZenecas_NN
omeprazole_JJ
formulation_NOMZ
patent_NN
._.
This_DEMO
judgement_NOMZ
was_VBD [BYPA]
confirmed_VBN [PUBV]
by_PIN
the_DT
Norwegian_JJ
Appeal_NN
Court_NN
in_PIN
October_NN
2005_CD
._.
In_PIN
January_NN
2006_CD
,_,
the_DT
Supreme_NN
Court_NN
in_PIN
Norway_NN
denied_VBD [PUBV] [THATD]
AstraZeneca_NN
leave_VPRT
to_TO
appeal_VB
._.
In_PIN
December_NN
2004_CD
,_,
an_DT
interlocutory_JJ
injunction_NOMZ
against_PIN
Nomeco_NN
A_NN
S_NN
,_,
a_DT
Danish_JJ
distributor_NN
of_PIN
a_DT
generic_JJ
omeprazole_NN
product_NN
from_PIN
ratiopharm_NN
,_,
was_VBD [PASS]
granted_VBN [SUAV]
in_PIN
Denmark_NN
based_VBN [WZPAST]
on_PIN
AstraZenecas_NN
omeprazole_NN
formulation_NOMZ
patent_NN
._.
The_DT
case_NN
was_VBD [PASS]
heard_VBN [PRIV]
on_PIN
appeal_NN
in_PIN
November_NN
and_PHC
December_NN
2005_CD
._.
The_DT
courts_NN
decision_NN
is_VPRT [PASS]
anticipated_VBN [PRIV]
in_PIN
February_NN
2006_CD
._.
AstraZeneca_NN
continues_VPRT
to_TO
be_VB [PASS]
involved_VBN
in_PIN
numerous_JJ
proceedings_GER
in_PIN
Canada_NN
involving_VBG [WZPRES]
Reddy_NN
Cheminor_NN
and_PHC
Apotex_NN
._.
These_DEMO
cases_NN
relate_VPRT
to_TO
omeprazole_VB
capsules_NN
or_CC
omeprazole_NN
magnesium_NN
tablets_NN
and_CC
involve_VB
various_JJ
patents_NN
._.
Apotex_NN
launched_VBD
a_DT
generic_JJ
omeprazole_NN
capsule_NN
product_NN
in_PIN
Canada_NN
in_PIN
January_NN
2004_CD
._.
Following_VBG [PRESP]
this_DEMO
launch_NN
,_,
AstraZeneca_NN
commenced_VBD
judicial_JJ
review_NN
proceedings_GER
seeking_VBG [WZPRES]
to_TO
quash_VB
Apotexs_NN
notice_NN
of_PIN
compliance_NN
marketing_GER
approval_NN
and_PHC
AstraZeneca_NN
sued_VBD
Apotex_NN
in_PIN
July_NN
2004_CD
alleging_VBG [PUBV]
infringement_NOMZ
of_PIN
its_PIT
formulation_NOMZ
patents_NN
by_PIN
Apotexs_NN
omeprazole_NN
capsules_NN
._.
In_PIN
May_POMD
2005_CD
,_,
the_DT
Canadian_NN
Federal_NN
Court_NN
of_PIN
Appeal_NN
quashed_VBD
Apotexs_NN
notice_NN
of_PIN
compliance_NN
marketing_GER
approval_NN
,_,
overruling_VBG [PRESP]
the_DT
first_JJ
instance_NN
decision_NN
in_PIN
September_NN
2004_CD
,_,
which_WDT [SERE]
went_VBD
against_PIN
AstraZeneca_NN
._.
In_PIN
June_NN
2005_CD
,_,
the_DT
Canadian_NN
Federal_NN
Court_NN
of_PIN
Appeal_NN
granted_VBD [SUAV]
Apotexs_NN
motion_NOMZ
for_PIN
a_DT
stay_NN
of_PIN
the_DT
courts_NN
decision_NN
to_TO
quash_VB
the_DT
notice_NN
of_PIN
compliance_NN
,_,
pending_VBG [PRESP]
an_DT
application_NOMZ
by_PIN
Apotex_NN
for_PIN
leave_NN
to_TO
appeal_VB
to_PIN
the_DT
Supreme_NN
Court_NN
of_PIN
Canada_NN
._.
The_DT
Supreme_NN
Court_NN
of_PIN
Canada_NN
has_VPRT [PEAS]
granted_VBN [SUAV] [THATD]
Apotex_NN
leave_VPRT
to_TO
appeal_VB
and_CC
the_DT
appeal_NN
is_VPRT [SPAU] [PASS]
tentatively_RB
scheduled_VBN
to_TO
be_VB [PASS]
heard_VBN [PRIV]
in_PIN
May_POMD
2006_CD
._.
The_DT
Supreme_NN
Court_NN
has_VPRT [SPAU] [PEAS]
also_RB
continued_VBN
the_DT
stay_NN
granted_VBN [SUAV] [WZPAST]
by_PIN
the_DT
Federal_NN
Court_NN
of_PIN
Appeal_NN
,_,
thereby_RB
allowing_VBG [SUAV]
Apotex_NN
to_TO
continue_VB
selling_VBG
its_PIT
omeprazole_NN
capsules_NN
pending_VBG [WZPRES]
a_DT
decision_NN
by_PIN
the_DT
Supreme_NN
Court_NN
on_PIN
Apotexs_NN
appeal_NN
._.
In_PIN
January_NN
2006_CD
,_,
AstraZeneca_NN
Canada_NN
Inc._NN
was_VBD [PASS]
served_VBN
with_PIN
a_DT
claim_NN
in_PIN
the_DT
Federal_NN
Court_NN
of_PIN
Canada_NN
for_PIN
payment_NOMZ
of_PIN
an_DT
undetermined_JJ
sum_NN
based_VBN [WZPAST]
on_PIN
damages_NN
allegedly_RB
suffered_VBN
by_PIN
Apotex_NN
due_JJ
to_PIN
the_DT
delay_NN
from_PIN
January_NN
2002_CD
to_PIN
January_NN
2004_CD
in_PIN
the_DT
issuance_NN
to_PIN
Apotex_NN
of_PIN
a_DT
notice_NN
of_PIN
compliance_NN
marketing_GER
approval_NN
in_PIN
Canada_NN
for_PIN
its_PIT
20mg_JJ
omeprazole_NN
capsule_NN
product_NN
._.
AstraZeneca_NN
believes_VPRT [PRIV] [THATD]
the_DT
claim_NN
is_VPRT [BEMA]
without_PIN
merit_NN
and_CC
intends_VPRT [SUAV]
to_TO
defend_VB
it_PIT
and_CC
to_TO
pursue_VB
its_PIT
already_RB
pending_VBG
patent_NN
infringement_NOMZ
action_NOMZ
against_PIN
Apotex_NN
vigorously_RB
._.
Financial_NN
Statements_NOMZ
121_CD
25_CD
COMMITMENTS_NOMZ
AND_CC
CONTINGENT_JJ
LIABILITIES_NOMZ
CONTINUED_VBD
In_PIN
February_NN
2000_CD
,_,
the_DT
European_JJ
Commission_NN
commenced_VBD
an_DT
investigation_NOMZ
relating_VBG [WZPRES]
to_PIN
certain_JJ
omeprazole_NN
intellectual_JJ
property_NN
rights_NN
,_,
and_ANDC
associated_VBN
regulatory_JJ
and_CC
patent_NN
infringement_NOMZ
litigation_NOMZ
._.
The_DT
investigation_NOMZ
is_VPRT [BEMA]
pursuant_PRED
to_PIN
Article_NN
82_CD
of_PIN
the_DT
EC_NN
Treaty_NN
,_,
which_WDT [SERE]
prohibits_VPRT
an_DT
abuse_NN
of_PIN
a_DT
dominant_JJ
position_NOMZ
._.
The_DT
investigation_NOMZ
was_VBD [BYPA]
precipitated_VBN
by_PIN
a_DT
complaint_NN
by_PIN
a_DT
party_NN
to_PIN
a_DT
number_NN
of_PIN
patent_NN
and_CC
other_JJ
proceedings_GER
involving_VBG [WZPRES]
AstraZeneca_NN
._.
AstraZeneca_NN
has_VPRT
,_,
in_PIN
accordance_NN
with_PIN
its_PIT
corporate_JJ
policy_NN
,_,
co-operated_JJ
with_PIN
the_DT
Commission_NN
._.
In_PIN
July_NN
2003_CD
,_,
the_DT
Commission_NN
served_VBD
a_DT
Statement_NOMZ
of_PIN
Objections_NOMZ
on_PIN
AstraZeneca_NN
,_,
referring_VBG
to_TO
alleged_VBN [PUBV] [THATD]
infringements_NOMZ
regarding_VBG [WZPRES]
the_DT
obtaining_VBG
of_PIN
supplementary_JJ
protection_NOMZ
certificates_NN
for_PIN
omeprazole_NN
in_PIN
certain_JJ
European_JJ
countries_NN
:_:
and_ANDC
regarding_VBG
AstraZenecas_NN
replacement_NOMZ
of_PIN
omeprazole_NN
capsules_NN
by_PIN
omeprazole_NN
MUPS_NN
tablets_NN
and_PHC
withdrawal_NN
of_PIN
capsule_NN
marketing_GER
authorisations_NOMZ
in_PIN
three_CD
European_JJ
countries_NN
._.
AstraZeneca_NN
replied_VBD [PUBV]
fully_AMP
to_PIN
the_DT
Commission_NN
,_,
explaining_VBG [PUBV] [PRESP]
why_RB [WHCL]
its_PIT
actions_NOMZ
were_VBD [BEMA]
in_PIN
AstraZenecas_NN
view_NN
lawful_JJ
._.
An_DT
oral_JJ
hearing_GER
took_VBD
place_NN
in_PIN
February_NN
2004_CD
._.
In_PIN
June_NN
2005_CD
,_,
the_DT
European_NN
Commission_NN
notified_VBD
AstraZeneca_NN
PLC_NN
and_PHC
AstraZeneca_NN
AB_NN
of_PIN
its_PIT
Decision_NN
to_TO
impose_VB
fines_NN
totalling60m_VB
on_PIN
the_DT
companies_NN
for_PIN
infringement_NOMZ
of_PIN
European_JJ
competition_NOMZ
law_NN
Article_NN
82_CD
of_PIN
the_DT
EC_NN
Treaty_NN
and_PHC
Article_NN
54_CD
of_PIN
the_DT
EEA_NN
Agreement_NOMZ
._.
The_DT
Commission_NN
alleges_VPRT [PUBV]
that_THVC
the_DT
companies_NN
abused_VBD
their_TPP3
dominant_JJ
positions_NOMZ
in_PIN
the_DT
periods_NN
between_PIN
1993_CD
and_CC
2000_CD
by_PIN
making_VBG
a_DT
pattern_NN
of_PIN
misleading_JJ
representations_NOMZ
before_IN
the_DT
patent_NN
offices_NN
and_CC
or_CC
courts_NN
in_PIN
Belgium_NN
,_,
Denmark_NN
,_,
Germany_NN
,_,
the_DT
Netherlands_NN
,_,
Norway_NN
and_CC
the_DT
UK_NN
in_PIN
regard_NN
to_TO
obtaining_VBG
supplementary_JJ
protection_NOMZ
certificates_NN
for_PIN
omeprazole_NN
:_:
and_ANDC
by_PIN
requesting_VBG [SUAV]
the_DT
surrender_NN
of_PIN
market_NN
authorisations_NOMZ
for_PIN
omeprazole_JJ
capsules_NN
in_PIN
Denmark_NN
,_,
Norway_NN
and_PHC
Sweden_NN
,_,
combined_VBN [PASTP]
with_PIN
withdrawal_NN
from_PIN
these_DEMO
countries_NN
of_PIN
omeprazole_NN
capsules_NN
and_CC
the_DT
launch_NN
of_PIN
omeprazole_NN
MUPS_NN
tablets_NN
._.
AstraZeneca_NN
does_VPRT
not_XX0
accept_VB [PRIV]
the_DT
Commissions_NN
Decision_NN
and_CC
has_VPRT [PEAS]
appealed_VBN
it_PIT
to_PIN
the_DT
Court_NN
of_PIN
First_NN
Instance_NN
._.
AstraZeneca_NN
denies_VPRT [PUBV]
that_THVC
it_PIT
had_VBD
a_DT
dominant_JJ
position_NOMZ
or_CC
that_THVC
it_PIT
was_VBD [PASS]
engaged_VBN
in_PIN
the_DT
behaviors_NN
as_IN
characterised_VBN
by_PIN
the_DT
Commission_NN
._.
In_PIN
the_DT
meantime_NN
,_,
the_DT
fine_NN
was_VBD [SPAU] [PASS]
fully_AMP
provided_VBN
for_PIN
in_PIN
the_DT
half_NN
year_NN
results_NN
through_PIN
a_DT
charge_NN
to_TO
operating_VBG
profit_NN
of_PIN
$_$
75m_CD
._.
It_PIT
is_VPRT [BYPA]
alleged_VBN [PUBV]
by_PIN
the_DT
Commission_NN
that_TOBJ
these_DEMO
activities_NOMZ
had_VBD
the_DT
effect_NN
of_PIN
hindering_VBG
the_DT
entry_NN
of_PIN
the_DT
generic_JJ
version_NN
of_PIN
Losec_NN
and_CC
parallel_JJ
trade_NN
._.
It_PIT
is_VPRT [BEMA]
possible_PRED
that_THAC
third_JJ
parties_NN
could_POMD
seek_VB
damages_NN
for_PIN
alleged_JJ
losses_NN
arising_VBG [WZPRES]
from_PIN
this_DEMO
matter_NN
._.
Any_QUAN
such_JJ
claims_NN
would_PRMD
be_VB [SPAU] [PASS]
vigorously_RB
resisted_VBN
._.
Nexium_NN
esomeprazole_NN
AstraZeneca_NN
entities_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
sued_VBN
in_PIN
various_JJ
state_NN
and_CC
federal_JJ
courts_NN
in_PIN
the_DT
US_FPP1
in_PIN
purported_JJ
representative_NN
and_PHC
class_NN
actions_NOMZ
involving_VBG [WZPRES]
the_DT
marketing_GER
of_PIN
Nexium_NN
esomeprazole_NN
._.
These_DEMO
actions_NOMZ
generally_RB
allege_VPRT [PUBV]
that_THVC
AstraZenecas_NN
promotion_NOMZ
and_PHC
advertising_GER
of_PIN
Nexium_NN
to_PIN
physicians_NN
and_PHC
consumers_NN
is_VPRT [BEMA]
unfair_PRED
,_,
unlawful_JJ
and_PHC
deceptive_JJ
conduct_NN
,_,
particularly_RB
as_IN
the_DT
promotion_NOMZ
relates_VPRT
to_PIN
comparisons_NN
of_PIN
Nexium_NN
with_PIN
Prilosec_NN
._.
They_TPP3
also_RB
allege_VPRT [PUBV]
that_THVC
AstraZenecas_NN
conduct_NN
relating_VBG [WZPRES]
to_PIN
the_DT
pricing_GER
of_PIN
Nexium_NN
was_VBD [BEMA]
unfair_PRED
,_,
unlawful_JJ
and_PHC
deceptive_JJ
._.
The_DT
plaintiffs_NN
allege_VPRT [PUBV]
claims_NN
under_IN
various_JJ
state_NN
consumer_NN
protection_NOMZ
,_,
unfair_JJ
practices_NN
and_CC
false_JJ
advertising_GER
laws_NN
._.
The_DT
plaintiffs_NN
in_PIN
these_DEMO
cases_NN
seek_VPRT
remedies_NN
that_TSUB
include_VPRT
restitution_NOMZ
,_,
disgorgement_NOMZ
of_PIN
profits_NN
,_,
damages_NN
,_,
punitive_JJ
damages_NN
,_,
injunctive_JJ
relief_NN
,_,
attorneys_NN
fees_NN
and_PHC
costs_NN
of_PIN
suit_NN
._.
The_DT
first_JJ
action_NOMZ
was_VBD [PASS]
brought_VBN
in_PIN
2004_CD
in_PIN
the_DT
Superior_NN
Court_NN
of_PIN
the_DT
State_NN
of_PIN
California_NN
for_PIN
the_DT
County_NN
of_PIN
Los_NN
Angeles_NN
by_PIN
the_DT
AFL-CIO_NN
,_,
two_CD
unincorporated_JJ
associations_NOMZ
and_CC
an_DT
individual_NN
on_PIN
behalf_NN
of_PIN
themselves_TPP3
,_,
the_DT
general_JJ
public_NN
and_CC
a_DT
class_NN
of_PIN
California_NN
consumers_NN
,_,
third_JJ
party_NN
payers_NN
,_,
cash_NN
payers_NN
and_CC
those_DEMP
making_VBG
co-pay_NN
._.
A_DT
second_JJ
action_NOMZ
was_VBD [PASS]
filed_VBN
in_PIN
the_DT
same_JJ
court_NN
on_PIN
behalf_NN
of_PIN
a_DT
similar_JJ
putative_JJ
class_NN
of_PIN
consumers_NN
._.
Actions_NOMZ
making_VBG [WZPRES]
substantially_RB
similar_JJ
allegations_NOMZ
were_VBD [PASS]
filed_VBN
in_PIN
2004_CD
and_CC
2005_CD
on_PIN
behalf_NN
of_PIN
putative_JJ
classes_NN
of_PIN
consumers_NN
,_,
third_JJ
party_NN
payers_NN
,_,
purchasers_NN
and_PHC
labor_NN
management_NOMZ
trust_NN
funds_NN
in_PIN
the_DT
Circuit_NN
Court_NN
of_PIN
Searcy_NN
County_NN
,_,
Arkansas_NN
:_:
in_PIN
the_DT
Superior_NN
Court_NN
of_PIN
the_DT
State_NN
of_PIN
Delaware_NN
in_PIN
and_CC
for_PIN
New_NN
Castle_NN
County_NN
:_:
in_PIN
the_DT
Superior_NN
Court_NN
of_PIN
Massachusetts_NN
in_PIN
Boston_NN
:_:
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
Delaware_NN
:_:
and_ANDC
in_PIN
the_DT
Circuit_NN
Court_NN
of_PIN
the_DT
11th_JJ
Judicial_NN
Court_NN
in_PIN
and_CC
for_PIN
Miami-Dade_NN
County_NN
,_,
Florida_NN
._.
In_PIN
September_NN
2005_CD
,_,
the_DT
court_NN
in_PIN
California_NN
issued_VBD
a_DT
ruling_NN
on_PIN
AstraZenecas_NN
demurrer_NN
and_PHC
motion_NOMZ
to_TO
strike_VB
in_PIN
the_DT
two_CD
California_NN
actions_NOMZ
._.
The_DT
court_NN
granted_VBD [SUAV]
AstraZenecas_NN
motion_NOMZ
with_PIN
respect_NN
to_PIN
the_DT
associational_JJ
plaintiffs_NN
and_CC
denied_VBD [PUBV]
the_DT
motion_NOMZ
with_PIN
respect_NN
to_PIN
the_DT
individual_JJ
plaintiffs_NN
,_,
allowing_VBG [SUAV] [PRESP]
the_DT
cases_NN
of_PIN
the_DT
individuals_NN
to_TO
proceed_VB
._.
In_PIN
October_NN
2005_CD
,_,
the_DT
court_NN
in_PIN
Massachusetts_NN
issued_VBD
an_DT
order_NN
denying_VBG [PUBV] [WZPRES]
AstraZenecas_NN
motion_NOMZ
to_TO
dismiss_VB
._.
In_PIN
November_NN
2005_CD
,_,
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
Delaware_NN
issued_VBD
an_DT
order_NN
granting_VBG [SUAV] [WZPRES]
AstraZenecas_NN
motion_NOMZ
to_TO
dismiss_VB
the_DT
consolidated_JJ
class_NN
action_NOMZ
complaint_NN
in_PIN
the_DT
three_CD
consolidated_JJ
Delaware_NN
actions_NOMZ
._.
AstraZeneca_NN
denies_VPRT [PUBV]
the_DT
allegations_NOMZ
and_CC
is_VPRT [SPAU]
vigorously_RB
defending_VBG
each_QUAN
of_PIN
these_DEMO
actions_NOMZ
._.
In_PIN
November_NN
2003_CD
,_,
the_DT
European_JJ
Patent_NN
Office_NN
ruled_VBD [SUAV]
that_THVC
the_DT
European_JJ
substance_NN
patent_NN
covering_VBG [WZPRES]
magnesium_NN
esomeprazole_NN
,_,
the_DT
active_JJ
pharmaceutical_JJ
ingredient_NN
in_PIN
Nexium_NN
,_,
is_VPRT [BEMA]
valid_PRED
._.
The_DT
patent_NN
,_,
which_WDT [SERE]
expires_VPRT
in_PIN
May_POMD
2014_CD
,_,
was_VBD [BYPA]
challenged_VBN
by_PIN
the_DT
generic_JJ
manufacturer_NN
ratiopharm_NN
._.
The_DT
European_JJ
Patent_NN
Office_NN
ruling_NN
has_VPRT [PEAS]
been_VBN [BYPA]
appealed_VBN
by_PIN
ratiopharm_NN
._.
It_PIT
is_VPRT [PASS]
not_XX0
anticipated_VBN [PRIV]
that_THVC
the_DT
appeal_NN
will_PRMD
be_VB [PASS]
heard_VBN [PRIV]
before_IN
the_DT
end_NN
of_PIN
2006_CD
._.
In_PIN
October_NN
2004_CD
,_,
AstraZeneca_NN
LP_NN
filed_VBD
suit_NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
Delaware_NN
seeking_VBG [WZPRES]
declaratory_JJ
judgement_NOMZ
that_TOBJ
its_PIT
Better_NN
is_VPRT
Better_RB
campaign_NN
for_PIN
Nexium_NN
is_VPRT [BEMA]
not_XX0
false_PRED
or_CC
misleading_JJ
advertising_GER
in_PIN
violation_NOMZ
of_PIN
section_NOMZ
43_CD
a_DT
of_PIN
the_DT
Lanham_NN
Act_NN
,_,
a_DT
federal_JJ
statute_NN
governing_VBG [WZPRES]
false_JJ
advertising_GER
claims_NN
._.
The_DT
action_NOMZ
was_VBD [PASS]
taken_VBN
in_PIN
response_NN
to_PIN
a_DT
letter_NN
from_PIN
TAP_NN
Pharmaceuticals_NN
,_,
Inc._NN
demanding_VBG [SUAV] [WZPRES]
that_THVC
AstraZeneca_NN
immediately_TIME
withdraw_VB
the_DT
television_NN
commercial_NN
and_CC
other_JJ
components_NN
of_PIN
the_DT
direct-to-consumer_NN
advertising_GER
campaign_NN
for_PIN
Nexium_NN
on_PIN
the_DT
basis_NN
that_TOBJ
they_TPP3
allegedly_RB
violated_VBD
the_DT
statute_NN
._.
In_PIN
November_NN
2004_CD
,_,
TAP_NN
requested_VBD [SUAV]
expedited_VBN
consideration_NOMZ
of_PIN
the_DT
case_NN
by_PIN
filing_VBG
a_DT
motion_NOMZ
for_PIN
a_DT
preliminary_JJ
injunction_NOMZ
and_CC
in_PIN
December_NN
2004_CD
,_,
the_DT
court_NN
denied_VBD [PUBV]
the_DT
request_NN
for_PIN
a_DT
preliminary_JJ
injunction_NOMZ
._.
The_DT
case_NN
is_VPRT [PASS]
scheduled_VBN
to_TO
be_VB [PASS]
tried_VBN
in_PIN
the_DT
second_JJ
or_CC
third_JJ
quarter_NN
of_PIN
2006_CD
._.
In_PIN
October_NN
2005_CD
,_,
AstraZeneca_NN
received_VBD
a_DT
notice_NN
from_PIN
Ranbaxy_NN
Pharmaceuticals_NN
,_,
Inc._NN
that_TOBJ
Ranbaxy_NN
Laboratories_NN
Limited_NN
had_VBD [PEAS]
submitted_VBN [PUBV]
an_DT
Abbreviated_NN
New_NN
Drug_NN
Application_NOMZ
to_PIN
the_DT
US_FPP1
FDA_NN
for_PIN
esomeprazole_NN
magnesium_NN
delayed-release_NN
capsules_NN
,_,
20mg_JJ
and_PHC
40mg_JJ
._.
The_DT
ANDA_NN
contained_VBD
paragraph_NN
IV_NN
certifications_NOMZ
of_PIN
invalidity_NOMZ
and_CC
or_CC
non-infringement_JJ
in_PIN
respect_NN
of_PIN
certain_JJ
AstraZeneca_NN
US_FPP1
patents_NN
listed_VBN [WZPAST]
in_PIN
the_DT
FDAs_NN
Orange_NN
Book_NN
with_PIN
reference_NN
to_PIN
Nexium_NN
._.
In_PIN
November_NN
2005_CD
,_,
AstraZeneca_NN
commenced_VBD
wilful_JJ
infringement_NOMZ
patent_NN
litigation_NOMZ
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
New_NN
Jersey_NN
against_PIN
Ranbaxy_NN
Pharmaceuticals_NN
,_,
Inc._NN
and_CC
its_PIT
affiliates_NN
in_PIN
response_NN
to_PIN
Ranbaxys_NN
paragraph_NN
IV_NN
certifications_NOMZ
regarding_VBG [WZPRES]
Nexium_NN
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
122_CD
Form_NN
20-F_JJ
Information_NOMZ
2005_CD
NOTES_NN
TO_PIN
THE_DT
FINANCIAL_NN
STATEMENTS_NOMZ
CONTINUED_VBD
25_CD
COMMITMENTS_NOMZ
AND_CC
CONTINGENT_JJ
LIABILITIES_NOMZ
CONTINUED_VBD
In_PIN
January_NN
2006_CD
,_,
AstraZeneca_NN
received_VBD
a_DT
notice_NN
from_PIN
IVAX_NN
Pharmaceuticals_NN
Inc._NN
that_TOBJ
IVAX_NN
Corporation_NOMZ
had_VBD [PEAS]
submitted_VBN [PUBV]
an_DT
ANDA_NN
to_TO
th_VB
e_SYM
US_FPP1
FDA_NN
for_PIN
esomeprazole_NN
magnesium_NN
delayed-release_NN
capsules_NN
,_,
20mg_JJ
and_PHC
40mg_JJ
._.
IVAX_NN
also_RB
certified_VBD [PUBV]
in_PIN
respect_NN
of_PIN
certain_JJ
other_JJ
AstraZeneca_NN
US_FPP1
patents_NN
listed_VBN [WZPAST]
in_PIN
the_DT
Orange_NN
Book_NN
with_PIN
reference_NN
to_PIN
Nexium_NN
that_TOBJ
IVAX_NN
will_PRMD
not_XX0
launch_VB
its_PIT
product_NN
prior_RB
to_PIN
the_DT
expiry_NN
of_PIN
those_DEMO
patents_NN
,_,
the_DT
latter_NN
of_PIN
which_WDT [PIRE]
expires_VPRT
in_PIN
October_NN
2007_CD
._.
The_DT
45_CD
day_NN
time_NN
period_NN
within_PIN
which_WDT [PIRE]
AstraZeneca_NN
can_POMD
commence_VB
a_DT
patent_NN
infringement_NOMZ
lawsuit_NN
against_PIN
IVAX_NN
that_TSUB
would_PRMD [SPAU]
automatically_RB
stay_VB
,_,
or_CC
bar_NN
,_,
the_DT
FDA_NN
from_PIN
approving_VBG
IVAX_NN
s_VPRT
ANDA_NN
for_PIN
30_CD
months_NN
or_CC
u_JJ
ntil_NN
an_DT
adverse_JJ
court_NN
decision_NN
,_,
whichever_WDT
occurs_VPRT
earlier_TIME
expires_VPRT
in_PIN
March_NN
2006_CD
._.
AstraZeneca_NN
continues_VPRT
to_TO
have_VB
full_JJ
confidence_NN
in_PIN
and_CC
will_PRMD [SPAU]
vigorously_RB
defend_VB
and_PHC
enforce_VB
its_PIT
intellectual_JJ
property_NN
protecting_VBG [WZPRES]
Nexium_NN
._.
Nolvadex_NN
tamoxifen_NN
AstraZeneca_NN
is_VPRT [BEMA]
a_DT
co-defendant_NN
with_PIN
Barr_NN
Laboratories_NN
,_,
Inc._NN
in_PIN
numerous_JJ
purported_JJ
class_NN
actions_NOMZ
filed_VBN [WZPAST]
in_PIN
federal_JJ
and_CC
state_NN
courts_NN
throughout_PIN
the_DT
US_FPP1
._.
All_QUAN
of_PIN
the_DT
state_NN
court_NN
actions_NOMZ
were_VBD [PASS]
removed_VBN
to_PIN
federal_JJ
court_NN
and_CC
have_VPRT [PEAS]
been_VBN [BEMA]
consolidated_PRED
,_,
along_IN
with_PIN
all_QUAN
of_PIN
the_DT
cases_NN
originally_TIME
filed_VBN
in_PIN
the_DT
federal_JJ
courts_NN
,_,
in_PIN
a_DT
federal_JJ
multi-district_JJ
litigation_NOMZ
proceeding_VBG [WZPRES]
pending_VBG
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Eastern_NN
District_NN
of_PIN
New_NN
York_NN
._.
Some_QUAN
of_PIN
the_DT
cases_NN
were_VBD [BYPA]
filed_VBN
by_PIN
plaintiffs_NN
representing_VBG [WZPRES]
a_DT
putative_JJ
class_NN
of_PIN
consumers_NN
who_WP [WHSUB]
purchased_VBD
tamoxifen_NN
._.
The_DT
other_JJ
cases_NN
were_VBD [PASS]
filed_VBN
on_PIN
behalf_NN
of_PIN
a_DT
putative_JJ
class_NN
of_PIN
third_JJ
party_NN
payers_NN
including_VBG [WZPRES]
health_NN
maintenance_NN
organizations_NOMZ
,_,
insurers_NN
and_CC
other_JJ
managed_VBN
care_NN
providers_NN
and_PHC
health_NN
plans_NN
that_TSUB
have_VPRT [PEAS]
reimbursed_VBN
or_CC
otherwise_CONJ
paid_VBN
for_PIN
prescriptions_NOMZ
of_PIN
tamoxifen_NN
._.
The_DT
plaintiffs_NN
allege_VPRT [PUBV]
that_THVC
they_TPP3
paid_VBD
supra-competitive_JJ
and_PHC
monopolistic_JJ
prices_NN
for_PIN
tamoxifen_NN
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
settlement_NOMZ
of_PIN
patent_NN
litigation_NOMZ
between_PIN
Zeneca_NN
and_PHC
Barr_NN
in_PIN
1993_CD
._.
The_DT
plaintiffs_NN
seek_VPRT
injunctive_JJ
relief_NN
,_,
treble_JJ
damages_NN
under_IN
the_DT
antitrust_JJ
laws_NN
,_,
disgorgement_NOMZ
and_PHC
restitution_NOMZ
._.
In_PIN
April_NN
2002_CD
,_,
AstraZeneca_NN
filed_VBD
a_DT
motion_NOMZ
to_TO
dismiss_VB
the_DT
cases_NN
for_PIN
failure_NN
to_TO
state_VB [PUBV]
a_DT
cause_NN
of_PIN
action_NOMZ
._.
In_PIN
May_POMD
2003_CD
,_,
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Eastern_NN
District_NN
of_PIN
New_NN
York_NN
granted_VBD [SUAV]
AstraZenecas_NN
motion_NOMZ
to_TO
dismiss_VB
._.
The_DT
plaintiffs_NN
appealed_VBD
the_DT
decision_NN
._.
In_PIN
November_NN
2005_CD
,_,
the_DT
US_FPP1
Court_NN
of_PIN
Appeals_NN
for_PIN
the_DT
Second_NN
Circuit_NN
affirmed_VBD [PUBV]
the_DT
District_NN
Courts_NN
decision_NN
._.
The_DT
plaintiffs_NN
have_VPRT [PEAS]
moved_VBN [SUAV]
for_PIN
re-hearing_GER
by_PIN
the_DT
original_JJ
panel_NN
of_PIN
judges_NN
in_PIN
the_DT
case_NN
and_PHC
re-hearing_GER
by_PIN
a_DT
panel_NN
of_PIN
all_QUAN
of_PIN
the_DT
judges_NN
on_PIN
the_DT
US_FPP1
Court_NN
of_PIN
Appeals_NN
for_PIN
the_DT
Second_NN
Circuit_NN
._.
Pulmicort_NN
Respules_NN
budesonide_NN
inhalation_NOMZ
suspension_NN
In_PIN
September_NN
2005_CD
,_,
AstraZeneca_NN
received_VBD
a_DT
notice_NN
from_PIN
IVAX_NN
Pharmaceuticals_NN
Inc._NN
that_TOBJ
IVAX_NN
had_VBD [PEAS]
submitted_VBN [PUBV]
an_DT
Abbreviated_NN
New_NN
Drug_NN
App_NN
lication_NOMZ
to_PIN
the_DT
US_FPP1
FDA_NN
for_PIN
a_DT
budesonide_NN
inhalation_NOMZ
suspension_NN
containing_VBG [WZPRES]
a_DT
paragraph_NN
IV_NN
certification_NOMZ
and_CC
alleging_VBG [PUBV]
invalidity_NOMZ
and_PHC
non-infringement_NOMZ
in_PIN
respect_NN
of_PIN
certain_JJ
of_PIN
AstraZenecas_NN
patents_NN
relating_VBG [WZPRES]
to_TO
budesonide_VB
inhalation_NOMZ
suspension_NN
._.
In_PIN
October_NN
2005_CD
,_,
AstraZeneca_NN
filed_VBD
a_DT
patent_NN
infringement_NOMZ
action_NOMZ
against_PIN
IVAX_NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
New_NN
Jersey_NN
._.
In_PIN
December_NN
2005_CD
,_,
IVAX_NN
responded_VBD
and_PHC
filed_VBD
counterclaims_NN
alleging_VBG [PUBV] [WZPRES]
no_SYNE
n-infringement_NOMZ
and_PHC
invalidity_NOMZ
._.
In_PIN
January_NN
2006_CD
,_,
AstraZeneca_NN
filed_VBD
an_DT
Amended_JJ
Complaint_NN
,_,
withdrawing_VBG
averments_NOMZ
as_IN
to_PIN
the_DT
infringement_NOMZ
of_PIN
one_CD
of_PIN
the_DT
patents-in-suit_NN
._.
AstraZeneca_NN
continues_VPRT
to_TO
have_VB
full_JJ
confidence_NN
in_PIN
and_CC
will_PRMD [SPAU]
vigorously_RB
defend_VB
and_PHC
enforce_VB
its_PIT
intellectual_JJ
property_NN
protecting_VBG [WZPRES]
Pulmicort_NN
Respules_NN
._.
Seroquel_NN
quetiapine_NN
fumarate_NN
AstraZeneca_NN
PLC_NN
and_PHC
AstraZeneca_NN
Pharmaceuticals_NN
LP_NN
were_VBD [PASS]
named_VBN
as_IN
defendants_NN
in_PIN
the_DT
case_NN
of_PIN
Susan_NN
Zehel-Miller_NN
et_FW
al._FW
._.
v._CC
AstraZenaca_NN
-LRB-_-LRB-
sic_JJ
-RRB-_-RRB-
,_,
AstraZenaca_NN
Pharmaceuticals_NN
,_,
LP_NN
-LRB-_-LRB-
sic_JJ
-RRB-_-RRB-
,_,
a_DT
putative_JJ
class_NN
action_NOMZ
suit_NN
filed_VBN [WZPAST]
in_PIN
August_NN
2003_CD
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Middl_NN
e_SYM
District_NN
of_PIN
Florida_NN
on_PIN
behalf_NN
of_PIN
a_DT
purported_JJ
class_NN
consisting_VBG [WZPRES]
of_PIN
all_QUAN
persons_NN
in_PIN
the_DT
US_FPP1
who_WP [WHSUB]
purchased_VBD
and_CC
or_CC
used_VBN
Seroquel_NN
contending_VBG [PUBV] [WZPRES]
that_THVC
AstraZeneca_NN
failed_VBD
to_TO
provide_VB
adequate_JJ
warnings_GER
in_PIN
connection_NOMZ
with_PIN
an_DT
alleged_JJ
association_NOMZ
between_PIN
Seroquel_NN
and_CC
the_DT
onset_NN
of_PIN
diabetes_NN
._.
In_PIN
the_DT
first_JJ
quarter_NN
of_PIN
2005_CD
,_,
subsequent_JJ
to_PIN
a_DT
2004_CD
court_NN
decision_NN
denying_VBG [PUBV] [WZPRES]
class_NN
certification_NOMZ
in_PIN
this_DEMO
matter_NN
,_,
the_DT
case_NN
was_VBD [PASS]
dismissed_VBN
with_PIN
prejudice_NN
._.
A_DT
second_JJ
Seroquel_NN
lawsuit_NN
involving_VBG [WZPRES]
a_DT
minor_JJ
who_WP
claimed_VBD [PUBV]
to_TO
have_VB [PEAS]
developed_VBN
diabetes_NN
mellitus_NN
as_CONJ
a_NULL
result_NULL
of_PIN
using_VBG
Seroquel_NN
was_VBD [SPAU] [PASS]
also_RB
dismissed_VBN
with_PIN
prejudice_NN
in_PIN
December_NN
2005_CD
,_,
approximately_RB
one_CD
week_NN
before_IN
oral_JJ
argument_NOMZ
on_PIN
AstraZenecas_NN
motion_NOMZ
for_PIN
summary_NN
judgement_NOMZ
was_VBD [PASS]
scheduled_VBN
to_TO
take_VB
place_NN
._.
Since_OSUB
2003_CD
,_,
AstraZeneca_NN
has_VPRT [PEAS]
been_VBN [PASS]
served_VBN
with_PIN
approximately_RB
60_CD
lawsuits_NN
in_PIN
the_DT
US_FPP1
in_PIN
which_WDT [PIRE]
plaintiffs_NN
have_VPRT [PEAS]
contended_VBN [PUBV]
that_THVC
they_TPP3
developed_VBD
diabetes_NN
or_CC
other_JJ
allegedly_RB
related_JJ
injuries_NN
as_CONJ
a_NULL
result_NULL
of_PIN
taking_VBG
Seroquel_NN
and_CC
or_CC
other_JJ
atypical_JJ
anti-psychotics_NN
made_VBN [WZPAST]
by_PIN
other_JJ
pharmaceutical_JJ
companies_NN
._.
About_IN
40_CD
of_PIN
these_DEMO
cases_NN
were_VBD [PASS]
filed_VBN
in_PIN
Missouri_NN
in_PIN
August_NN
2005_CD
,_,
days_NN
before_IN
Missouris_NN
tort_NN
reform_NN
laws_NN
became_VBD
effective_JJ
._.
Eli_NN
Lilly_NN
,_,
the_DT
maker_NN
of_PIN
olanzapine_NN
,_,
is_VPRT [BEMA]
a_DT
defendant_NN
in_PIN
the_DT
majority_NOMZ
of_PIN
the_DT
cases_NN
served_VBD
on_PIN
AstraZeneca_NN
._.
Janssen_NN
Pharmaceutica_NN
and_PHC
Bristol-Myers_NN
Squibb_NN
are_VPRT [SPAU]
also_RB
defending_VBG
a_DT
number_NN
of_PIN
them_TPP3
._.
AstraZeneca_NN
is_VPRT [BEMA]
also_RB
aware_PRED
of_PIN
more_EMPH
than_PIN
100_CD
other_JJ
cases_NN
involving_VBG [WZPRES]
Seroquel_NN
that_TSUB
have_VPRT [SPAU] [PEAS]
recently_TIME
been_VBN [PASS]
filed_VBN
in_PIN
California_NN
,_,
Delaware_NN
,_,
Illinois_NN
,_,
Louisiana_NN
,_,
Missouri_NN
,_,
New_NN
Jersey_NN
and_PHC
Texas_NN
,_,
but_CC
these_DEMP
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
served_VBN
._.
One_CD
involves_VPRT
a_DT
putative_JJ
nationwide_JJ
class_NN
action_NOMZ
complaint_NN
,_,
which_WDT [SERE]
was_VBD [SPAU] [PASS]
recently_TIME
filed_VBN
in_PIN
federal_JJ
court_NN
in_PIN
the_DT
Southern_NN
District_NN
of_PIN
Illinois_NN
._.
AstraZeneca_NN
has_VPRT [PEAS]
seen_VBN [PRIV]
this_DEMO
complaint_NN
and_CC
it_PIT
is_VPRT [BEMA]
very_AMP
similar_PRED
in_PIN
form_NN
and_PHC
content_NN
to_PIN
the_DT
complaint_NN
filed_VBN [WZPAST]
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Middle_NN
District_NN
of_PIN
Florida_NN
in_PIN
2003_CD
Susan_NN
Zehel-Miller_NN
et_FW
al._FW
._.
v._CC
AstraZenaca_NN
-LRB-_-LRB-
sic_JJ
-RRB-_-RRB-
,_,
Astr_NN
aZenaca_NN
Pharmaceuticals_NN
LP_NN
,_,
-LRB-_-LRB-
sic_JJ
-RRB-_-RRB-
,_,
described_VBN
above_PLACE
that_DEMP
sought_VBD
certification_NOMZ
of_PIN
a_DT
nationwide_JJ
class_NN
of_PIN
Seroquel_NN
users_NN
and_PHC
others_NN
,_,
including_VBG
individuals_NN
who_WP [WHSUB]
were_VBD [PASS]
alleged_VBN [PUBV]
to_TO
have_VB [PEAS]
developed_VBN
diabetes_NN
as_CONJ
a_NULL
result_NULL
of_PIN
using_VBG
Seroquel_NN
._.
The_DT
federal_JJ
court_NN
in_PIN
Florida_NN
denied_VBD [PUBV]
certification_NOMZ
of_PIN
the_DT
class_NN
in_PIN
the_DT
Zehel-Miller_NN
case_NN
._.
In_PIN
early_TIME
2005_CD
,_,
after_IN
the_DT
plaintiffs_NN
efforts_NN
in_PIN
that_DEMO
case_NN
to_TO
secure_VB
appellate_JJ
relief_NN
failed_VBD
,_,
the_DT
plaintiffs_NN
agreed_VBD [SUAV] [PUBV]
to_PIN
a_DT
voluntary_JJ
dismissal_NN
of_PIN
all_QUAN
of_PIN
their_TPP3
claims_NN
with_PIN
prejudice_NN
._.
It_PIT
is_VPRT [BEMA]
possible_PRED
that_THAC
plaintiffs_NN
lawyers_NN
are_VPRT
contemplating_VBG
the_DT
filing_NN
of_PIN
potentially_RB
numerous_JJ
lawsuits_NN
against_PIN
AstraZeneca_NN
and_CC
other_JJ
manufacturers_NN
of_PIN
atypical_JJ
anti-psychotics_NN
involving_VBG [WZPRES]
allegations_NOMZ
of_PIN
diabetes_NN
._.
AstraZeneca_NN
intends_VPRT [SUAV]
to_TO
defend_VB
vigorously_RB
all_QUAN
of_PIN
the_DT
pending_VBG
cases_NN
relating_VBG [WZPRES]
to_PIN
Seroquel_NN
._.
In_PIN
September_NN
2005_CD
,_,
AstraZeneca_NN
received_VBD
a_DT
notice_NN
from_PIN
Teva_NN
Pharmaceuticals_NN
USA_NN
that_TOBJ
Teva_NN
had_VBD [PEAS]
submitted_VBN [PUBV]
an_DT
Abbreviated_NN
New_NN
Drug_NN
Application_NOMZ
ANDA_NN
for_PIN
quetiapine_NN
fumarate_NN
tablets_NN
25mg_JJ
base_NN
to_PIN
the_DT
US_FPP1
FDA_NN
._.
The_DT
ANDA_NN
contained_VBD
a_DT
paragraph_NN
IV_NN
certification_NOMZ
alleging_VBG [PUBV] [WZPRES]
invalidity_NOMZ
and_PHC
noninfringement_NOMZ
in_PIN
respect_NN
of_PIN
AstraZenecas_NN
US_FPP1
patent_NN
listed_VBN [WZPAST]
in_PIN
the_DT
FDAs_NN
Orange_NN
Book_NN
with_PIN
reference_NN
to_PIN
Seroquel_NN
._.
In_PIN
November_NN
2005_CD
,_,
in_PIN
response_NN
to_PIN
Tevas_NN
ANDA_NN
and_PHC
Tevas_NN
intent_NN
to_TO
market_VB
a_DT
generic_JJ
version_NN
of_PIN
Seroquel_NN
in_PIN
the_DT
US_FPP1
prior_RB
to_PIN
the_DT
expiration_NOMZ
of_PIN
AstraZenecas_NN
patent_NN
,_,
AstraZeneca_NN
filed_VBD
a_DT
lawsuit_NN
against_PIN
Teva_NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
New_NN
Jersey_NN
for_PIN
wilful_JJ
patent_NN
infringement_NOMZ
._.
AstraZeneca_NN
continues_VPRT
to_TO
have_VB
full_JJ
confidence_NN
in_PIN
and_CC
will_PRMD [SPAU]
vigorously_RB
defend_VB
and_PHC
enforce_VB
its_PIT
intellectual_JJ
property_NN
protecting_VBG [WZPRES]
Seroquel_NN
._.
Financial_NN
Statements_NOMZ
123_CD
25_CD
COMMITMENTS_NOMZ
AND_CC
CONTINGENT_JJ
LIABILITIES_NOMZ
CONTINUED_VBD
Symbicort_NN
budesonide_NN
formoterol_NN
In_PIN
March_NN
2005_CD
,_,
the_DT
European_JJ
Patent_NN
Office_NN
ruled_VBD [SUAV]
that_THVC
the_DT
European_JJ
patent_NN
covering_VBG [WZPRES]
the_DT
combination_NOMZ
of_PIN
formoterol_NN
and_PHC
budesonide_NN
in_PIN
Symbicort_NN
is_VPRT [BEMA]
valid_PRED
._.
The_DT
patent_NN
,_,
which_WDT [SERE]
expires_VPRT
in_PIN
2012_CD
,_,
was_VBD [BYPA]
challenged_VBN
by_PIN
the_DT
generic_JJ
manufacturers_NN
Yamanouchi_NN
Europe_NN
BV_NN
,_,
Miat_NN
SpA_NN
,_,
Liconsa_NN
,_,
Chiesi_NN
Farmaceutici_NN
SpA_NN
,_,
Zambon_NN
Group_NN
SpA_NN
,_,
Generics_NN
UK_NN
Limited_NN
and_PHC
Norton_NN
Healthcare_NN
Ltd._NN
._.
In_PIN
May_POMD
2005_CD
,_,
the_DT
European_JJ
Patent_NN
Office_NN
ruled_VBD [SUAV]
that_THVC
the_DT
European_JJ
patent_NN
for_PIN
Symbicort_NN
in_PIN
the_DT
treatment_NOMZ
of_PIN
chronic_JJ
obstructive_JJ
pulmonary_JJ
disease_NN
COPD_NN
is_VPRT [BEMA]
valid_PRED
._.
The_DT
patent_NN
,_,
which_WDT [SERE]
expires_VPRT
in_PIN
2018_CD
,_,
was_VBD [BYPA]
challenged_VBN
by_PIN
the_DT
generic_JJ
manufacturers_NN
Chiesi_NN
Farmaceutici_NN
SpA_NN
,_,
Norton_NN
Healthcare_NN
Ltd_NN
and_PHC
Generics_NN
UK_NN
Limited_NN
._.
The_DT
European_JJ
Patent_NN
Office_NN
rulings_GER
relating_VBG [WZPRES]
to_PIN
both_DT
the_DT
combination_NOMZ
and_CC
the_DT
COPD_NN
European_NN
patents_NN
for_PIN
Symbicort_NN
have_VPRT [PEAS]
been_VBN [BYPA]
appealed_VBN
by_PIN
certain_JJ
of_PIN
the_DT
opponents_NN
in_PIN
the_DT
proceedings_GER
._.
It_PIT
is_VPRT [PASS]
not_XX0
anticipated_VBN [PRIV]
that_THVC
the_DT
appeals_NN
will_PRMD
be_VB [PASS]
heard_VBN [PRIV]
before_IN
2007_CD
._.
In_PIN
February_NN
2004_CD
,_,
IVAX_NN
Pharmaceuticals_NN
UK_NN
Limited_NN
initiated_VBD
proceedings_GER
against_PIN
AstraZeneca_NN
AB_NN
claiming_VBG [PUBV] [WZPRES]
that_THVC
the_DT
UK_NN
parts_NN
of_PIN
t_NN
he_TPP3
two_CD
European_JJ
patents_NN
related_VBN [WZPAST]
to_PIN
Symbicort_NN
were_VBD [BEMA]
invalid_PRED
._.
In_PIN
May_POMD
2004_CD
,_,
the_DT
court_NN
granted_VBD [SUAV]
AstraZenecas_NN
application_NOMZ
for_PIN
a_DT
stay_NN
of_PIN
the_DT
proceedings_GER
pending_VBG [WZPRES]
the_DT
determination_NOMZ
of_PIN
the_DT
parallel_JJ
opposition_NOMZ
proceedings_GER
before_IN
the_DT
European_JJ
Patent_NN
Office_NN
,_,
described_VBD
above_PLACE
._.
In_PIN
April_NN
2004_CD
,_,
IVAX_NN
ini_FW
tiated_VBN
proceedings_GER
against_PIN
AstraZeneca_NN
AB_NN
in_PIN
relation_NOMZ
to_PIN
the_DT
Republic_NN
of_PIN
Ireland_NN
claiming_VBG [PUBV] [WZPRES]
that_THVC
the_DT
Irish_JJ
parts_NN
of_PIN
the_DT
two_CD
European_JJ
patents_NN
related_VBN [WZPAST]
to_PIN
Symbicort_NN
were_VBD [BEMA]
invalid_PRED
._.
In_PIN
October_NN
2004_CD
,_,
the_DT
court_NN
granted_VBD [SUAV]
AstraZenecas_NN
application_NOMZ
for_PIN
a_DT
stay_NN
of_PIN
proceedings_GER
pending_VBG [WZPRES]
the_DT
final_JJ
decision_NN
of_PIN
the_DT
European_JJ
Patent_NN
Office_NN
and_CC
its_PIT
Boards_NN
of_PIN
Appeal_NN
in_PIN
the_DT
opposition_NOMZ
proceedings_GER
._.
Toprol-XL_JJ
metoprolol_NN
succinate_VB
In_PIN
May_POMD
2003_CD
,_,
AstraZeneca_NN
filed_VBD
a_DT
patent_NN
infringement_NOMZ
action_NOMZ
against_PIN
KV_NN
Pharmaceutical_NN
Company_NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Eastern_NN
District_NN
of_PIN
Missouri_NN
in_PIN
response_NN
to_PIN
KVs_NN
notification_NOMZ
of_PIN
its_PIT
intention_NOMZ
to_TO
market_VB
a_DT
generic_JJ
version_NN
of_PIN
Toprol-XL_JJ
tablets_NN
in_PIN
the_DT
200mg_JJ
dose_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
of_PIN
AstraZenecas_NN
patents_NN
covering_VBG [WZPRES]
the_DT
substance_NN
and_CC
its_PIT
formulation_NOMZ
._.
In_PIN
response_NN
to_TO
later_TIME
similar_JJ
notices_NN
from_PIN
KV_NN
related_VBN [WZPAST]
to_PIN
the_DT
25mg_JJ
,_,
50mg_JJ
and_PHC
100mg_JJ
doses_NN
,_,
AstraZeneca_NN
filed_VBD
further_JJ
actions_NOMZ
._.
KV_NN
responded_VBD
in_PIN
each_QUAN
instance_NN
and_CC
filed_VBD
counterclaims_NN
alleging_VBG [PUBV] [WZPRES]
non-infringement_JJ
,_,
invalidity_NOMZ
and_PHC
unenforceability_NOMZ
of_PIN
the_DT
listed_VBN
patents_NN
._.
In_PIN
February_NN
2004_CD
,_,
AstraZeneca_NN
filed_VBD
a_DT
patent_NN
infringement_NOMZ
action_NOMZ
against_PIN
Andrx_NN
Pharmaceuticals_NN
LLC_NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
Delaware_NN
in_PIN
response_NN
to_PIN
Andrxs_NN
notification_NOMZ
of_PIN
its_PIT
intention_NOMZ
to_TO
market_VB
a_DT
generic_JJ
version_NN
of_PIN
Toprol-XL_JJ
tablets_NN
in_PIN
the_DT
50mg_JJ
dose_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
of_PIN
AstraZenecas_NN
patents_NN
._.
In_PIN
response_NN
to_PIN
two_CD
later_TIME
similar_JJ
notices_NN
from_PIN
Andrx_NN
related_VBN [WZPAST]
to_PIN
the_DT
25mg_JJ
,_,
100mg_JJ
and_PHC
200mg_JJ
doses_NN
,_,
AstraZeneca_NN
filed_VBD
two_CD
additional_JJ
patent_NN
infringement_NOMZ
actions_NOMZ
in_PIN
the_DT
same_JJ
court_NN
._.
In_PIN
each_QUAN
instance_NN
,_,
Andrx_NN
claimed_VBD [PUBV]
that_THVC
each_QUAN
of_PIN
the_DT
listed_VBN
patents_NN
is_VPRT [BEMA]
invalid_PRED
,_,
not_XX0
infringed_VBN
and_CC
unenforceable_JJ
._.
In_PIN
April_NN
2004_CD
,_,
AstraZeneca_NN
filed_VBD
a_DT
patent_NN
infringement_NOMZ
action_NOMZ
against_PIN
Eon_NN
Labs_NN
Manufacturing_GER
Inc._NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
Delaware_NN
in_PIN
response_NN
to_PIN
Eons_NN
notification_NOMZ
of_PIN
its_PIT
intention_NOMZ
to_PIN
market_NN
generic_JJ
versions_NN
of_PIN
Toprol-XL_JJ
tablets_NN
in_PIN
the_DT
25mg_JJ
,_,
50mg_JJ
,_,
100mg_JJ
and_PHC
200mg_JJ
doses_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
of_PIN
AstraZenecas_NN
patents_NN
._.
In_PIN
its_PIT
response_NN
,_,
Eon_NN
alleged_VBD [PUBV]
that_THVC
each_QUAN
of_PIN
the_DT
listed_VBN
patents_NN
is_VPRT [BEMA]
invalid_PRED
,_,
not_XX0
infringed_VBN
and_CC
unenforceable_JJ
._.
Eon_NN
also_RB
alleged_VBD [PUBV]
that_THVC
the_DT
filing_NN
of_PIN
the_DT
infringement_NOMZ
complaints_NN
,_,
as_RB
well_RB
as_IN
other_JJ
actions_NOMZ
by_PIN
AstraZeneca_NN
,_,
constitutes_VPRT
anti-competitive_JJ
conduct_NN
in_PIN
violation_NOMZ
of_PIN
US_FPP1
anti-trust_JJ
laws_NN
._.
Pursuant_JJ
to_PIN
a_DT
joint_JJ
motion_NOMZ
of_PIN
AstraZeneca_NN
and_PHC
Eon_NN
these_DEMO
anti-trust_JJ
counts_NN
were_VBD [PASS]
severed_VBN
from_PIN
the_DT
case_NN
and_CC
stayed_VBD
,_,
for_PIN
possible_JJ
consideration_NOMZ
depending_VBG [WZPRES]
on_PIN
the_DT
outcome_NN
of_PIN
the_DT
trial_NN
of_PIN
the_DT
patent_NN
claims_NN
._.
In_PIN
January_NN
2005_CD
,_,
AstraZeneca_NN
filed_VBD
a_DT
terminal_NN
disclaimer_NN
of_PIN
the_DT
Toprol-XL_NN
patents-in-suit_NN
over_IN
one_CD
of_PIN
the_DT
other_JJ
patents_NN
raised_VBN [WZPAST]
by_PIN
the_DT
defendants_NN
,_,
which_WDT [SERE]
will_PRMD
result_VB
in_PIN
a_DT
revision_NN
of_PIN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
Toprol-XL_NN
patents-in-suit_NN
from_PIN
March_NN
2008_CD
to_PIN
September_NN
2007_CD
._.
All_QUAN
of_PIN
the_DT
patent_NN
litigation_NOMZ
relating_VBG [WZPRES]
to_PIN
Toprol-XL_NN
against_PIN
KV_NN
,_,
Andrx_NN
and_PHC
Eon_NN
was_VBD [PASS]
consolidated_VBN
for_PIN
pre-trial_JJ
discovery_NN
purposes_NN
and_PHC
motion_NOMZ
practice_NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Eastern_NN
District_NN
of_PIN
Missouri_NN
._.
The_DT
defendants_NN
filed_VBD
a_DT
motion_NOMZ
for_PIN
summary_NN
judgement_NOMZ
in_PIN
December_NN
2004_CD
alleging_VBG [PUBV]
that_THVC
the_DT
Toprol-XL_JJ
patents_NN
are_VPRT [BEMA]
invalid_JJ
due_JJ
to_TO
double_VB
patenting_GER
._.
A_DT
summary_NN
judgement_NOMZ
motion_NOMZ
of_PIN
unenforceability_NOMZ
was_VBD [BYPA]
filed_VBN
by_PIN
the_DT
defendants_NN
in_PIN
2005_CD
and_CC
AstraZeneca_NN
filed_VBD
summary_NN
judgement_NOMZ
motions_NOMZ
on_PIN
infringement_NOMZ
and_PHC
validity_NOMZ
in_PIN
2005_CD
._.
Oral_JJ
argument_NOMZ
on_PIN
all_QUAN
of_PIN
the_DT
pending_VBG
summary_NN
judgement_NOMZ
motions_NOMZ
was_VBD [PASS]
heard_VBN [PRIV]
in_PIN
November_NN
2005_CD
._.
In_PIN
January_NN
2006_CD
,_,
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Eastern_NN
District_NN
of_PIN
Missouri_NN
issued_VBD
a_DT
ruling_NN
finding_VBG [PRIV] [WZPRES]
that_THVC
the_DT
two_CD
patents-in-suit_NN
are_VPRT [BEMA]
unenforceable_PRED
based_VBN
on_PIN
the_DT
Companys_NN
inequitable_JJ
conduct_NN
in_PIN
the_DT
prosecution_NOMZ
of_PIN
these_DEMO
patents_NN
in_PIN
the_DT
US_FPP1
Patent_NN
and_PHC
Trademark_NN
Office_NN
and_CC
invalid_JJ
._.
AstraZeneca_NN
disagrees_VPRT
with_PIN
and_CC
is_VPRT [BYPA]
disappointed_VBN
by_PIN
these_DEMO
conclusions_NN
._.
It_PIT
will_PRMD
appeal_VB
this_DEMO
decision_NN
to_PIN
the_DT
US_FPP1
Court_NN
of_PIN
Appeals_NN
for_PIN
the_DT
Federal_NN
Circuit_NN
._.
None_INPR
of_PIN
the_DT
Abbreviated_NN
New_NN
Drug_NN
Applications_NOMZ
filed_VBN [WZPAST]
by_PIN
KV_NN
,_,
Andrx_NN
or_CC
Eon_NN
has_VPRT [PEAS]
received_VBN
tentative_JJ
approval_NN
from_PIN
the_DT
US_FPP1
Food_NN
and_PHC
Drug_NN
Administration_NOMZ
._.
Under_IN
the_DT
ANDA_NN
statute_NN
,_,
the_DT
January_NN
2006_CD
adverse_JJ
decision_NN
concerning_VBG [WZPRES]
the_DT
validity_NOMZ
and_PHC
enforceability_NOMZ
of_PIN
the_DT
AstraZeneca_NN
patents-in-suit_NN
automatically_RB
removes_VPRT
any_QUAN
stay_NN
on_PIN
the_DT
FDAs_NN
authority_NOMZ
to_TO
grant_VB [SUAV]
a_DT
final_JJ
approval_NN
of_PIN
the_DT
ANDAs_NN
._.
In_PIN
January_NN
2006_CD
,_,
AstraZeneca_NN
was_VBD [PASS]
served_VBN
with_PIN
a_DT
complaint_NN
filed_VBN [WZPAST]
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
Delaware_NN
entitled_VBD
Meijer_NN
,_,
Inc._NN
and_PHC
Meijer_NN
Distribution_NOMZ
,_,
Inc._NN
v._CC
AstraZeneca_NN
Pharmaceuticals_NN
LP_NN
,_,
AstraZeneca_NN
LP_NN
,_,
AstraZeneca_NN
AB_NN
and_PHC
Aktiebolaget_NN
Hassle_NN
._.
The_DT
complaint_NN
is_VPRT [BEMA]
a_DT
putative_JJ
class_NN
action_NOMZ
that_TSUB
alleges_VPRT [PUBV]
that_THVC
the_DT
AstraZeneca_NN
defendants_NN
attempted_VBD
to_TO [SPIN]
illegally_RB
maintain_VB [PUBV]
monopoly_NN
power_NN
in_PIN
the_DT
US_FPP1
over_IN
Toprol-XL_NN
in_PIN
violation_NOMZ
of_PIN
the_DT
Sherman_NN
Act_NN
through_PIN
the_DT
listing_GER
of_PIN
invalid_JJ
and_PHC
unenforceable_JJ
patents_NN
in_PIN
the_DT
FDAs_NN
Orange_NN
Book_NN
and_CC
the_DT
enforcement_NOMZ
of_PIN
such_JJ
patents_NN
through_PIN
litigation_NOMZ
against_PIN
generic_JJ
manufacturers_NN
seeking_VBG [WZPRES]
to_PIN
market_NN
metoprolol_NN
succinate_NN
._.
The_DT
complaint_NN
seeks_VPRT
treble_JJ
damages_NN
based_VBN [WZPAST]
on_PIN
alleged_JJ
overcharges_NN
to_PIN
the_DT
putative_JJ
class_NN
of_PIN
plaintiffs_NN
._.
The_DT
lawsuit_NN
is_VPRT [PASS]
based_VBN
upon_PIN
the_DT
finding_VBG [PRIV]
described_VBN
above_PLACE
by_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Eastern_NN
District_NN
of_PIN
Missouri_NN
in_PIN
the_DT
consolidated_JJ
litigation_NOMZ
against_PIN
KV_NN
,_,
Andrx_NN
and_PHC
Eon_NN
that_TOBJ
the_DT
AstraZeneca_NN
patents_NN
relating_VBG [WZPRES]
to_PIN
Toprol-XL_NN
are_VPRT [BEMA]
invalid_PRED
and_PHC
unenforceable_PRED
._.
As_IN
noted_VBN [PRIV]
above_PLACE
,_,
AstraZeneca_NN
is_VPRT
appealing_VBG
this_DEMO
ruling_NN
in_PIN
the_DT
patent_NN
litigation_NOMZ
._.
AstraZeneca_NN
denies_VPRT [PUBV]
the_DT
allegations_NOMZ
of_PIN
this_DEMO
anti-trust_JJ
complaint_NN
and_CC
will_PRMD [SPAU]
vigorously_RB
defend_VB
the_DT
lawsuit_NN
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
124_CD
Form_NN
20-F_JJ
Information_NOMZ
2005_CD
NOTES_NN
TO_PIN
THE_DT
FINANCIAL_NN
STATEMENTS_NOMZ
CONTINUED_VBD
25_CD
COMMITMENTS_NOMZ
AND_CC
CONTINGENT_JJ
LIABILITIES_NOMZ
CONTINUED_VBD
AstraZeneca_NN
continues_VPRT
to_TO
maintain_VB [PUBV]
that_THVC
its_PIT
patents_NN
for_PIN
Toprol-XL_NN
are_VPRT [BEMA]
valid_PRED
,_,
enforceable_JJ
and_CC
infringed_VBN
by_PIN
the_DT
proposed_VBN [SUAV]
generic_JJ
products_NN
of_PIN
KV_NN
,_,
Andrx_NN
and_PHC
Eon_NN
and_CC
that_THVC
its_PIT
enforcement_NOMZ
of_PIN
its_PIT
patents_NN
did_VBD
not_XX0
violate_VB
anti-trust_JJ
laws_NN
._.
Zestril_NN
lisinopril_NN
In_PIN
1996_CD
,_,
two_CD
of_PIN
AstraZenecas_NN
predecessor_NN
companies_NN
,_,
Zeneca_NN
Limited_NN
and_PHC
Zeneca_NN
Pharma_NN
Inc._NN
as_IN
licensees_NN
,_,
Merck_NN
&_CC
Co._NN
._.
Inc._NN
and_PHC
Merck_NN
Frosst_NN
Canada_NN
Inc._NN
commenced_VBD
a_DT
patent_NN
infringement_NOMZ
action_NOMZ
in_PIN
the_DT
Federal_NN
Court_NN
of_PIN
Canada_NN
against_PIN
Apotex_NN
Inc._NN
alleging_VBG [PUBV] [WZPRES]
infringement_NOMZ
of_PIN
Mercks_NN
lisinopril_NN
patent_NN
._.
Apotex_NN
has_VPRT [PEAS]
sold_VBN
and_PHC
continues_VPRT
to_TO
sell_VB
a_DT
generic_JJ
version_NN
of_PIN
AstraZenecas_NN
Zestril_NN
and_PHC
Mercks_NN
Prinivil_NN
tablets_NN
._.
Apotex_NN
has_VPRT [PEAS]
admitted_VBN [PUBV]
infringement_NOMZ
but_CC
has_VPRT [PEAS]
raised_VBN
positive_JJ
defences_NN
to_PIN
infringement_NOMZ
,_,
including_VBG
that_DEMO
it_PIT
acquired_VBD
certain_JJ
quantities_NOMZ
of_PIN
lisinopril_NN
prior_RB
to_PIN
issuance_NN
of_PIN
the_DT
patent_NN
and_CC
that_DEMO
certain_JJ
quantities_NOMZ
were_VBD [PASS]
licensed_VBN
under_IN
a_DT
compulsory_JJ
licence_NN
._.
Apotex_NN
has_VPRT [SPAU] [PEAS]
also_RB
alleged_VBN [PUBV]
invalidity_NOMZ
of_PIN
the_DT
patent_NN
._.
The_DT
trial_NN
started_VBD
in_PIN
January_NN
2006_CD
._.
AstraZeneca_NN
as_IN
licensee_NN
has_VPRT
a_DT
case_NN
pending_VBG [WZPRES]
in_PIN
the_DT
Federal_NN
Court_NN
of_PIN
Canada_NN
against_PIN
Cobalt_NN
Pharmaceuticals_NN
Inc._NN
pertaining_VBG [WZPRES]
to_PIN
the_DT
same_JJ
Merck_NN
lisinopril_NN
patent_NN
,_,
on_PIN
the_DT
basis_NN
that_TOBJ
Cobalt_NN
is_VPRT
seeking_VBG
a_DT
notice_NN
of_PIN
compliance_NN
marketing_GER
approval_NN
in_PIN
Canada_NN
based_VBN [WZPAST]
on_PIN
a_DT
comparison_NN
with_PIN
AstraZenecas_NN
Zestril_NN
._.
AstraZeneca_NN
is_VPRT [BEMA]
potentially_RB
liable_PRED
for_PIN
damages_NN
in_PIN
the_DT
event_NN
that_TSUB
Cobalts_VPRT
market_NN
entry_NN
is_VPRT [PASS]
held_VBN [PRIV]
to_TO
have_VB [PEAS]
been_VBN [SPAU] [PASS]
improperly_RB
delayed_VBN
._.
Zestoretic_JJ
lisinopril_NN
hydrochlorothiazide_NN
AstraZeneca_NN
as_IN
licensee_NN
has_VPRT
a_DT
case_NN
pending_VBG [WZPRES]
in_PIN
the_DT
Federal_NN
Court_NN
of_PIN
Canada_NN
against_PIN
Apotex_NN
Inc._NN
pertaining_VBG [WZPRES]
to_PIN
Mercks_NN
lisinopril_NN
hydrochlorothiazide_NN
combination_NOMZ
patent_NN
,_,
on_PIN
the_DT
basis_NN
that_TOBJ
Apotex_NN
is_VPRT
seeking_VBG
a_DT
notice_NN
of_PIN
compliance_NN
marketing_GER
approval_NN
in_PIN
Canada_NN
based_VBN [WZPAST]
on_PIN
a_DT
comparison_NN
with_PIN
AstraZenecas_NN
Zestoretic_NN
._.
AstraZeneca_NN
is_VPRT [BEMA]
potentially_RB
liable_PRED
for_PIN
damages_NN
in_PIN
the_DT
event_NN
that_TSUB
Apotexs_VPRT
market_NN
entry_NN
is_VPRT [PASS]
held_VBN [PRIV]
to_TO
have_VB [PEAS]
been_VBN [SPAU] [PASS]
improperly_RB
delayed_VBN
._.
Average_JJ
wholesale_JJ
price_NN
class_NN
action_NOMZ
litigation_NOMZ
In_PIN
January_NN
2002_CD
,_,
AstraZeneca_NN
was_VBD [PASS]
named_VBN
as_IN
a_DT
defendant_NN
along_IN
with_PIN
24_CD
other_JJ
pharmaceutical_JJ
manufacturers_NN
in_PIN
a_DT
class_NN
action_NOMZ
suit_NN
,_,
in_PIN
Massachusetts_NN
,_,
brought_VBD
on_PIN
behalf_NN
of_PIN
a_DT
putative_JJ
class_NN
of_PIN
plaintiffs_NN
alleged_VBN [PUBV]
to_TO
have_VB [PEAS]
overpaid_VBN
for_PIN
prescription_NOMZ
drugs_NN
as_CONJ
a_NULL
result_NULL
of_PIN
inflated_JJ
wholesale_JJ
list_NN
prices_NN
._.
The_DT
suit_NN
seeks_VPRT
to_TO
recover_VB
unspecified_JJ
damages_NN
._.
Following_VBG [PRESP]
the_DT
Massachusetts_NN
complaint_NN
,_,
nearly_DWNT
identical_JJ
class_NN
action_NOMZ
suits_NN
were_VBD [PASS]
filed_VBN
against_PIN
AstraZeneca_NN
and_CC
various_JJ
other_JJ
pharmaceutical_JJ
manufacturers_NN
in_PIN
four_CD
other_JJ
states_NN
._.
AstraZeneca_NN
and_CC
other_JJ
manufacturers_NN
have_VPRT
since_OSUB
been_VBN [PASS]
sued_VBN
in_PIN
similar_JJ
lawsuits_NN
filed_VBN [WZPAST]
by_PIN
the_DT
state_NN
Attorneys_NN
General_NN
of_PIN
Pennsylvania_NN
,_,
Nevada_NN
,_,
Montana_NN
,_,
Wisconsin_NN
,_,
Illinois_NN
,_,
Alabama_NN
,_,
Kentucky_NN
,_,
Arizona_NN
and_PHC
Mississippi_NN
,_,
as_RB
well_RB
as_IN
by_PIN
multiple_JJ
individual_JJ
counties_NN
in_PIN
the_DT
State_NN
of_PIN
New_NN
York_NN
._.
The_DT
Attorney_NN
General_NN
lawsuits_NN
seek_VPRT
to_TO
recover_VB
alleged_JJ
overpayments_NOMZ
under_IN
Medicaid_NN
and_CC
other_JJ
state-funded_JJ
healthcare_NN
programs_NN
._.
In_PIN
several_QUAN
cases_NN
,_,
the_DT
states_NN
are_VPRT [SPAU]
also_RB
suing_VBG
to_TO
recover_VB
alleged_JJ
overpayments_NOMZ
by_PIN
state_NN
residents_NN
._.
Many_QUAN
of_PIN
these_DEMO
suits_NN
have_VPRT [PEAS]
been_VBN [PASS]
consolidated_VBN
with_PIN
the_DT
Massachusetts_NN
action_NOMZ
for_PIN
pre-trial_JJ
purposes_NN
,_,
pursuant_JJ
to_PIN
federal_JJ
multi-district_JJ
litigation_NOMZ
procedures_NN
._.
In_PIN
August_NN
2005_CD
,_,
the_DT
District_NN
Court_NN
in_PIN
Boston_NN
issued_VBD
a_DT
decision_NN
on_PIN
class_NN
certification_NOMZ
favourable_JJ
to_PIN
the_DT
defendants_NN
._.
The_DT
plaintiffs_NN
in_PIN
the_DT
consolidated_JJ
class_NN
action_NOMZ
suit_NN
had_VBD [PEAS]
sought_VBN
to_TO
certify_VB [PUBV]
three_CD
types_NN
of_PIN
nationwide_JJ
classes_NN
of_PIN
plaintiffs_NN
:_:
1_CD
Medicare_NN
Part_NN
B_NN
beneficiaries_NN
who_WP [WHSUB]
paid_VBD
allegedly_RB
inflated_JJ
co-insurance_NN
for_PIN
certain_JJ
drugs_NN
reimbursed_VBN
under_IN
the_DT
Medicare_NN
Part_NN
B_NN
program_NN
:_:
2_CD
third_JJ
party_NN
insurers_NN
offering_VBG [WZPRES]
coverage_NN
for_PIN
the_DT
same_JJ
drugs_NN
:_:
and_ANDC
3_CD
third_JJ
party_NN
insurers_NN
for_PIN
certain_JJ
self-administered_JJ
non-Part_JJ
B_NN
drugs_NN
._.
The_DT
court_NN
denied_VBD [PUBV]
the_DT
self-administered_JJ
drug_NN
class_NN
entirely_AMP
._.
As_IN
to_PIN
the_DT
proposed_VBN [SUAV] [THATD]
classes_NN
involving_VBG [WZPRES]
drugs_NN
,_,
the_DT
court_NN
certified_VBD [PUBV]
a_DT
nationwide_JJ
class_NN
of_PIN
Part_NN
B_NN
beneficiaries_NN
against_PIN
AstraZeneca_NN
and_CC
three_CD
other_JJ
manufacturers_NN
._.
The_DT
additional_JJ
proposed_VBN [SUAV] [THATD]
classes_NN
involving_VBG [WZPRES]
drugs_NN
,_,
third_JJ
party_NN
payers_NN
who_WP [WHSUB]
reimbursed_VBD
for_PIN
drugs_NN
or_CC
who_WP
covered_VBD
Part_NN
B_NN
co-payments_NOMZ
,_,
have_VPRT [PEAS]
been_VBN [PASS]
certified_VBN [PUBV]
only_DWNT
as_IN
Massachusetts_NN
state_NN
,_,
as_IN
opposed_VBN
to_PIN
nationwide_JJ
,_,
classes_NN
._.
For_PIN
all_QUAN
classes_NN
,_,
the_DT
only_DWNT
AstraZeneca_NN
drug_NN
at_PIN
issue_NN
is_VPRT
Zoladex_NN
goserelin_NN
acetate_NN
implant_VPRT
._.
There_EX
is_VPRT
a_DT
possibility_NOMZ
that_TOBJ
the_DT
decision_NN
on_PIN
class_NN
certification_NOMZ
will_PRMD
be_VB [PASS]
appealed_VBN
._.
Following_VBG [PRESP]
a_DT
decision_NN
on_PIN
the_DT
appeal_NN
,_,
the_DT
court_NN
will_PRMD
set_VB
a_DT
schedule_NN
for_PIN
summary_NN
judgement_NOMZ
proceedings_GER
and_PHC
trial_NN
._.
In_PIN
the_DT
interim_NN
,_,
Attorney_NN
General_NN
cases_NN
are_VPRT
proceeding_VBG
independently_RB
of_PIN
the_DT
consolidated_JJ
action_NOMZ
in_PIN
Pennsylvania_NN
,_,
Alabama_NN
,_,
Mississippi_NN
,_,
Arizona_NN
and_PHC
Wisconsin_NN
._.
AstraZeneca_NN
denies_VPRT [PUBV] [THATD]
the_DT
allegations_NOMZ
made_VBN [WZPAST]
in_PIN
all_QUAN
of_PIN
the_DT
average_JJ
wholesale_JJ
price_NN
lawsuits_NN
and_CC
will_PRMD [SPAU]
vigorously_RB
defend_VB
the_DT
actions_NOMZ
._.
340b_JJ
class_NN
action_NOMZ
litigation_NOMZ
In_PIN
August_NN
2004_CD
,_,
AstraZeneca_NN
was_VBD [PASS]
named_VBN
as_IN
a_DT
defendant_NN
along_IN
with_PIN
multiple_JJ
other_JJ
pharmaceutical_JJ
manufacturers_NN
in_PIN
a_DT
class_NN
action_NOMZ
suit_NN
filed_VBN [WZPAST]
in_PIN
the_DT
Alabama_NN
federal_JJ
court_NN
on_PIN
behalf_NN
of_PIN
all_QUAN
share_NN
entities_NOMZ
._.
These_DEMP
are_VPRT [BEMA]
the_DT
hospitals_NN
and_PHC
clinics_NN
that_TSUB
treat_VPRT
a_DT
substantial_JJ
portion_NOMZ
of_PIN
uninsured_JJ
patients_NN
and_ANDC
thus_CONJ
qualify_VB
for_PIN
preferential_JJ
pricing_GER
under_IN
the_DT
US_FPP1
Public_NN
Health_NN
Service_NN
Act_NN
drug_NN
discount_NN
program_NN
the_DT
340b_JJ
program_NN
._.
According_VBG [PRESP]
to_PIN
the_DT
complaint_NN
,_,
the_DT
genesis_NN
of_PIN
the_DT
suit_NN
is_VPRT [BEMA]
an_DT
audit_NN
report_NN
by_PIN
the_DT
US_FPP1
Department_NOMZ
of_PIN
Health_NN
and_PHC
Human_NN
Services_NN
Office_NN
of_PIN
Inspector_NN
General_NN
OIG_NN
in_PIN
June_NN
2004_CD
._.
A_DT
similar_JJ
class_NN
action_NOMZ
suit_NN
was_VBD [PASS]
filed_VBN
in_PIN
August_NN
2005_CD
by_PIN
the_DT
County_NN
of_PIN
Santa_NN
Clara_NN
in_PIN
the_DT
California_NN
state_NN
court_NN
._.
In_PIN
the_DT
second_JJ
suit_NN
,_,
the_DT
County_NN
of_PIN
Santa_NN
Clara_NN
is_VPRT
suing_VBG
as_IN
a_DT
representative_NN
of_PIN
a_DT
class_NN
of_PIN
similarly_CONJ
situated_VBN
counties_NN
and_PHC
cities_NOMZ
in_PIN
California_NN
alleged_VBD [PUBV]
to_TO
have_VB [PEAS]
overpaid_VBN
for_PIN
340b_JJ
drugs_NN
._.
AstraZeneca_NN
believes_VPRT [PRIV]
the_DT
allegations_NOMZ
in_PIN
both_DT
of_PIN
these_DEMO
lawsuits_NN
are_VPRT [BEMA]
without_PIN
merit_NN
and_CC
intends_VPRT [SUAV]
to_TO
defend_VB
them_TPP3
vigorously_RB
._.
Financial_NN
Statements_NOMZ
125_CD
25_CD
COMMITMENTS_NOMZ
AND_CC
CONTINGENT_JJ
LIABILITIES_NOMZ
CONTINUED_VBD
Additional_JJ
government_NOMZ
investigations_NOMZ
into_PIN
drug_NN
marketing_GER
practices_NN
As_IN
is_VPRT [BEMA]
true_PRED
for_PIN
most_EMPH
,_,
if_COND
not_XX0
all_QUAN
,_,
major_JJ
prescription_NOMZ
pharmaceutical_JJ
companies_NN
operating_VBG [WZPRES]
in_PIN
the_DT
US_FPP1
,_,
AstraZeneca_NN
is_VPRT [SPAU] [PASS]
currently_RB
involved_VBN
in_PIN
multiple_JJ
US_FPP1
federal_JJ
and_CC
state_NN
criminal_JJ
and_PHC
civil_JJ
investigations_NOMZ
into_PIN
drug_NN
marketing_GER
and_PHC
pricing_GER
practices_NN
._.
Two_CD
of_PIN
the_DT
active_JJ
investigations_NOMZ
are_VPRT
being_VBG [BYPA]
handled_VBN
by_PIN
the_DT
US_FPP1
Attorneys_NN
Office_NN
in_PIN
Boston_NN
._.
The_DT
first_JJ
involves_VPRT
a_DT
request_NN
for_PIN
production_NOMZ
of_PIN
documents_NOMZ
and_PHC
information_NOMZ
relating_VBG [WZPRES]
to_PIN
speaker_NN
programs_NN
involving_VBG [WZPRES]
healthcare_NN
professionals_NN
at_PIN
three_CD
regional_JJ
healthcare_NN
entities_NOMZ
in_PIN
the_DT
Boston_NN
area_NN
._.
The_DT
second_JJ
involves_VPRT
a_DT
subpoena_NN
for_PIN
documents_NOMZ
and_PHC
information_NOMZ
relating_VBG [WZPRES]
to_PIN
marketing_GER
and_PHC
sales_NN
interactions_NOMZ
with_PIN
a_DT
leading_VBG
provider_NN
of_PIN
pharmacy_NN
services_NN
to_PIN
long_JJ
term_NN
care_NN
facilities_NOMZ
._.
In_PIN
October_NN
2004_CD
,_,
AstraZeneca_NN
received_VBD
a_DT
subpoena_NN
from_PIN
the_DT
US_FPP1
Attorneys_NN
Office_NN
in_PIN
Philadelphia_NN
principally_RB
seeking_VBG
documents_NOMZ
relating_VBG [WZPRES]
to_PIN
the_DT
formulary_JJ
status_NN
of_PIN
AstraZeneca_NN
drugs_NN
at_PIN
a_DT
regional_JJ
health_NN
maintenance_NN
organization_NOMZ
and_CC
a_DT
national_JJ
pharmacy_NN
benefits_NN
manager_NN
._.
Most_EMPH
recently_TIME
,_,
AstraZeneca_NN
,_,
along_IN
with_PIN
12_CD
other_JJ
pharmaceutical_JJ
manufacturers_NN
,_,
was_VBD [PASS]
served_VBN
with_PIN
a_DT
subpoena_NN
from_PIN
the_DT
US_FPP1
Attorneys_NN
Office_NN
in_PIN
Philadelphia_NN
seeking_VBG [WZPRES]
documents_NOMZ
in_PIN
connection_NOMZ
with_PIN
the_DT
governments_NOMZ
pending_VBG [WZPRES]
civil_JJ
litigation_NOMZ
against_PIN
Medco_NN
Health_NN
Systems_NN
._.
That_DEMO
subpoena_NN
seeks_VPRT
documents_NOMZ
relating_VBG [WZPRES]
to_PIN
contracts_NN
,_,
programs_NN
,_,
grants_NN
or_CC
payments_NOMZ
to_PIN
Medco_NN
._.
In_PIN
January_NN
2006_CD
,_,
AstraZeneca_NN
first_RB
received_VBD
notice_NN
of_PIN
an_DT
investigation_NOMZ
by_PIN
the_DT
US_FPP1
Attorneys_NN
Office_NN
in_PIN
Los_NN
Angeles_NN
into_PIN
field_NN
promotional_JJ
activities_NOMZ
in_PIN
the_DT
area_NN
served_VBN [WZPAST]
by_PIN
AstraZenecas_NN
Los_NN
Angeles_NN
regional_JJ
business_NOMZ
center_NN
._.
AstraZeneca_NN
has_VPRT [PEAS]
been_VBN [PASS]
provided_VBN
with_PIN
little_JJ
information_NOMZ
concerning_VBG [WZPRES]
the_DT
nature_NN
of_PIN
the_DT
investigation_NOMZ
,_,
other_JJ
than_PIN
a_DT
representation_NOMZ
that_TOBJ
the_DT
government_NOMZ
is_VPRT
looking_VBG
into_PIN
the_DT
preparation_NOMZ
and_PHC
dissemination_NOMZ
of_PIN
patient_JJ
education_NOMZ
and_CC
similar_JJ
materials_NN
to_PIN
physicians_NN
._.
It_PIT
is_VPRT [BEMA]
not_XX0
possible_PRED
to_TO
predict_VB [PUBV]
the_DT
outcome_NN
of_PIN
any_QUAN
of_PIN
these_DEMO
investigations_NOMZ
,_,
which_WDT [SERE]
could_POMD
include_VB
the_DT
payment_NOMZ
of_PIN
damages_NN
and_CC
the_DT
imposition_NOMZ
of_PIN
fines_NN
,_,
penalties_NN
and_CC
administrative_JJ
remedies_NN
._.
Drug_NN
importation_NOMZ
anti-trust_JJ
litigation_NOMZ
In_PIN
May_POMD
2004_CD
,_,
plaintiffs_NN
in_PIN
a_DT
purported_JJ
class_NN
action_NOMZ
filed_VBD
complaints_NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
Minnesota_NN
and_CC
for_PIN
New_NN
Jersey_NN
,_,
alleging_VBG [PUBV]
that_THVC
AstraZeneca_NN
Pharmaceuticals_NN
LP_NN
and_CC
eight_CD
other_JJ
pharmaceutical_JJ
manufacturer_NN
defendants_NN
conspired_VBD
to_TO
prevent_VB
American_JJ
consumers_NN
from_PIN
purchasing_VBG
prescription_NOMZ
drugs_NN
from_PIN
Canada_NN
,_,
depriving_VBG
consumers_NN
of_PIN
the_DT
ability_NOMZ
to_TO
purchase_VB
drugs_NN
at_PIN
competitive_JJ
prices_NN
._.
The_DT
New_NN
Jersey_NN
case_NN
was_VBD [SPAU] [PASS]
voluntarily_RB
dismissed_VBN
in_PIN
July_NN
2004_CD
._.
In_PIN
August_NN
2005_CD
,_,
the_DT
Minnesota_NN
District_NN
Court_NN
dismissed_VBD
with_PIN
prejudice_NN
the_DT
plaintiffs_NN
federal_JJ
anti-trust_JJ
claims_NN
and_CC
declined_VBD
to_TO
exercise_VB
supplemental_JJ
jurisdiction_NOMZ
in_PIN
relation_NOMZ
to_PIN
the_DT
state_NN
statutory_JJ
and_PHC
common_JJ
law_NN
claims_NN
,_,
which_WDT [SERE]
claims_VPRT [PUBV]
were_VBD [PASS]
dismissed_VBN
without_PIN
prejudice_NN
._.
The_DT
plaintiffs_NN
have_VPRT [PEAS]
appealed_VBN
the_DT
district_NN
courts_NN
decision_NN
._.
In_PIN
August_NN
2004_CD
,_,
Californian_NN
retail_JJ
pharmacy_NN
plaintiffs_NN
filed_VBD
an_DT
action_NOMZ
in_PIN
the_DT
Superior_NN
Court_NN
of_PIN
California_NN
making_VBG [WZPRES]
similar_JJ
allegations_NOMZ
._.
In_PIN
July_NN
2005_CD
,_,
the_DT
court_NN
overruled_VBD
in_PIN
part_NN
and_CC
sustained_VBN
in_PIN
part_NN
,_,
without_PIN
leave_NN
to_TO
amend_VB
,_,
the_DT
defendants_NN
motion_NOMZ
to_TO
dismiss_VB
the_DT
plaintiffs_NN
third_JJ
amended_VBN
complaint_NN
in_PIN
these_DEMO
proceedings_GER
._.
The_DT
court_NN
overruled_VBD
the_DT
defendants_NN
motion_NOMZ
in_PIN
respect_NN
of_PIN
conspiracy_NN
claims_NN
but_CC
sustained_VBD
the_DT
motion_NOMZ
in_PIN
respect_NN
of_PIN
the_DT
California_NN
Unfair_NN
Competition_NOMZ
Law_NN
claims_VPRT [PUBV]
._.
Discovery_NN
is_VPRT [BEMA]
ongoing_PRED
and_CC
the_DT
trial_NN
is_VPRT [PASS]
scheduled_VBN
for_PIN
September_NN
2006_CD
._.
AstraZeneca_NN
denies_VPRT [PUBV]
the_DT
material_NN
allegations_NOMZ
of_PIN
both_DT
the_DT
Minnesota_NN
and_PHC
California_NN
actions_NOMZ
and_CC
is_VPRT [SPAU]
vigorously_RB
defending_VBG
these_DEMO
matters_NN
._.
StarLink_NN
AstraZeneca_NN
Insurance_NN
Company_NN
Limited_NN
AZIC_NN
has_VPRT [PEAS]
commenced_VBN
arbitration_NOMZ
proceedings_GER
in_PIN
the_DT
UK_NN
against_PIN
insurers_NN
in_PIN
respect_NN
of_PIN
amounts_NN
paid_VBN [WZPAST]
by_PIN
Garst_NN
Seed_NN
Company_NN
of_PIN
the_DT
US_FPP1
in_PIN
settlement_NOMZ
of_PIN
claims_NN
arising_VBG [WZPRES]
in_PIN
the_DT
US_FPP1
from_PIN
Garsts_NN
sale_NN
of_PIN
StarLink_NN
,_,
a_DT
genetically_RB
engineered_VBN
corn_NN
seed_NN
._.
The_DT
English_NN
High_NN
Court_NN
has_VPRT [PEAS]
ruled_VBN [SUAV]
,_,
on_PIN
appeal_NN
by_PIN
reinsurers_NN
from_PIN
a_DT
preliminary_JJ
finding_GER
in_PIN
AZICs_NN
favor_NN
by_PIN
the_DT
arbitration_NOMZ
panel_NN
,_,
that_THVC
English_NN
law_NN
applies_VPRT
to_PIN
recovery_NN
under_IN
the_DT
reinsurance_NN
arrangements_NOMZ
._.
This_DEMP
is_VPRT [BEMA]
contrary_PRED
to_PIN
AZICs_NN
view_NN
,_,
which_WDT [SERE]
is_VPRT
that_DEMO
recovery_NN
should_NEMD
be_VB [PASS]
assessed_VBN
under_IN
Iowa_NN
law_NN
,_,
and_ANDC
AZIC_NN
is_VPRT
seeking_VBG
leave_NN
to_TO
appeal_VB
this_DEMO
finding_GER
to_PIN
the_DT
Court_NN
of_PIN
Appeal_NN
._.
AstraZenecas_NN
interest_NN
in_PIN
Garst_NN
was_VBD [BEMA]
through_PIN
AstraZenecas_NN
50_CD
%_NN
ownership_NN
of_PIN
Advanta_NN
BV_NN
,_,
the_DT
sale_NN
of_PIN
which_WDT [PIRE]
to_PIN
Syngenta_NN
AG_NN
was_VBD [PASS]
announced_VBN [PUBV]
in_PIN
May_POMD
2004_CD
and_CC
completed_VBN
in_PIN
September_NN
2004_CD
._.
AZICs_NN
claim_VPRT [PUBV]
against_PIN
the_DT
insurers_NN
was_VBD [BYPA]
not_XX0
affected_VBN
by_PIN
the_DT
disposal_NN
of_PIN
AstraZenecas_NN
interest_NN
in_PIN
Advanta_NN
BV_NN
._.
Aptium_NN
Oncology_NN
In_PIN
April_NN
2004_CD
,_,
Comprehensive_NN
Cancer_NN
Centers_NN
,_,
Inc._NN
._.
CCC_NN
,_,
a_DT
subsidiary_NN
of_PIN
Aptium_NN
Oncology_NN
formerly_TIME
called_VBD
Salick_NN
Health_NN
Care_NN
received_VBD
a_DT
subpoena_NN
from_PIN
the_DT
US_FPP1
Department_NOMZ
of_PIN
Justice_NN
seeking_VBG [WZPRES]
,_,
among_PIN
other_JJ
items_NN
,_,
medical_JJ
records_NN
and_CC
related_VBN
documentation_NOMZ
for_PIN
services_NN
provided_VBN [WZPAST]
to_PIN
patients_NN
at_PIN
the_DT
Comprehensive_NN
Cancer_NN
Center_NN
at_PIN
Desert_NN
Regional_NN
Medical_NN
Center_NN
in_PIN
Palm_NN
Springs_GER
,_,
California_NN
._.
The_DT
Center_NN
is_VPRT [BYPA]
managed_VBN
by_PIN
CCC_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
co-operating_JJ
fully_AMP
with_PIN
the_DT
document_NOMZ
request_NN
._.
Avorelin_NN
In_PIN
1999_CD
,_,
AstraZeneca_NN
UK_NN
Limited_NN
entered_VBD
into_PIN
a_DT
licence_NN
agreement_NOMZ
with_PIN
Mediolanum_NN
farmaceutici_NN
SpA_NN
under_IN
which_WDT
Mediolanum_NN
licensed_VBD
to_PIN
AstraZeneca_NN
certain_JJ
rights_NN
in_PIN
respect_NN
of_PIN
avorelin_NN
,_,
a_DT
luteinising_VBG
hormone-releasing_GER
hormone_NN
agonist_NN
._.
At_PIN
the_DT
end_NN
of_PIN
2000_CD
,_,
AstraZeneca_NN
terminated_VBD
the_DT
agreement_NOMZ
._.
Mediolanum_NN
commenced_VBD
proceedings_GER
against_PIN
AstraZeneca_NN
alleging_VBG [PUBV] [WZPRES]
that_THVC
AstraZeneca_NN
breached_VBD
the_DT
terms_NN
of_PIN
the_DT
agreement_NOMZ
and_CC
claiming_VBG [PUBV]
damages_NN
._.
This_DEMO
matter_NN
has_VPRT [SPAU] [PEAS]
now_TIME
been_VBN [BYPA]
settled_VBN
by_PIN
the_DT
parties_NN
on_PIN
terms_NN
satisfactory_JJ
to_PIN
AstraZeneca_NN
which_WDT [WHSUB]
admits_VPRT [PUBV]
no_SYNE
liability_NOMZ
._.
